POSEIDON study: a pilot, safety and feasibility trial of high-dose omega-3 fatty acids and high-dose cholecalciferol supplementation in type 1 diabetes


Diabetes Research Institute and Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA

Corresponding Author: Camillo Ricordi, MD; e-mail: ricordi@miami.edu

The anti-inflammatory and immunomodulatory properties of high-dose omega-3 fatty acids and Vitamin D, and the initial encouraging results from case reports on the use of this supplementation in new-onset Type 1 Diabetes (T1D), support further testing of this combination strategy. This intervention appears to be well tolerated, affordable, and sufficiently safe to be further tested in randomized prospective trials to determine whether this combination therapy may be of assistance to halt progression of autoimmunity and/or preserve residual beta-cell function in subjects with new onset and established T1D of up to 10 years duration. In addition, the 1st PreDiRe T1D conference (Preventing Disease and its Recurrence in Type 1 Diabetes – see Editorial in this issue) was organized to discuss initial results and possible alternative/complementary strategies, for collaborative international expansion of these trials, to include strategies for disease prevention.

Our POSEIDON clinical trial will test the use of high dose vitamin D3 and highly purified Omega-3 fatty acids in new onset and established T1D. The draft of the study protocol, in addition to the informed consent and assent, is now shared open access to facilitate its international implementation by interested physicians and centers that would like to further test this approach through clinical trials.
A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol Supplementation in Type 1 Diabetes

POSEIDON STUDY: PILOT STUDY OF OMEGA-3 AND VITAMIN D HIGH DOSES IN T1D

VERSION 3.1 dated March 8, 2018

SPONSOR(S)
Camillo Ricordi, M.D.
Rodolfo Alejandro, M.D.

PRINCIPAL INVESTIGATOR
David Alejandro Baidal, M.D.

CO-PRINCIPAL INVESTIGATOR
Janine Sanchez, M.D.
PREFACE

PILOT STUDY OF OMEGA-3 AND VITAMIN D HIGH DOSES IN T1D (POSEIDON) Protocol, A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol Supplementation in Type 1 Diabetes, describes the background, design, and organization of the study. The Diabetes Research Institute will maintain the protocol over the course of the study through new releases of the protocol, or issuance of updates either in the form of revisions of complete chapters or pages thereof, or in the form of supplemental protocol memoranda.

AUTHORSHIP TEAM (in alphabetical order)

The following individuals provided substantial input during protocol development:

- Rodolfo Alejandro, M.D. "
- David Alejandro Baidal, M.D. *
- Carlos Eduardo Blaschke, F.M.G.
- Khemraj Hirani, Ph.D., RPh, RAC, CHRC
- Della Lorraine Matheson, R.N., CDE
- Shari Messinger, M.E., Ph.D.
- Alberto Pugliese, M.D.
- Lisa Emily Rafkin, MS, RD, CDE
- Camillo Ricordi, M.D. "
- Luis A. Roque, Quality Assurance Auditor
- Janine Sanchez, M.D. *
- Juliana Maria Vera Ortiz, M.D.

* Principal/Co-Investigator(s)
Ψ Sponsor

The sponsors, investigators, DRI leadership and study authors appreciate support and feedback from patient advocacy group such as Children with Diabetes in the creation and design of this study.
Glossary of Abbreviations

AE  Adverse event
APC  Antigen presenting cell
ATG  Anti-Thymocyte Globulin (Thymoglobulin®)
AUC  Area under Curve
BB Rat  Bio-Breeding Rat
CBC  Complete blood count
CFR  Code of Federal Regulations
cGMP  Current Good Manufacturing Practice
CHO  Carbohydrates
CMV  Cytomegalovirus
CRF  Case report form
CRS  Cytokine Release Syndrome
DC  Dendritic Cell
DRI  Diabetes Research Institute
DSMB  Data and Safety Monitoring Board
EBV  Epstein-Barr virus
FACS  Fluorescence activated cell sorting
FDA  US Food and Drug Administration
FOXP3  Forkhead box P3
FWA  Federal-wide Assurance
GAD  Glutamate decarboxylase
GCP  Good Clinical Practice
GCSF  Granulocyte colony-stimulating factor (GCSF/Neulasta®)
HbA1c  Hemoglobin A1c
HBsAg  Hepatitis B surface antigen
HIV  Human immunodeficiency virus
ICA  Islet cytoplasmic antibodies
IGRA  Interferon-γ release assays
IL-2  Interleukin 2
IND  Investigational New Drug
IRB  Institutional Review Board
LIFT  Long Term Investigative Follow-Up
MMTT  Mixed-meal tolerance test
NCI-CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events
NOD  Nonobese diabetic
OHRP  Office for Human Research Protections
PBMC  Peripheral Blood Mononuclear Cell
PCR  Polymerase chain reaction
PI  Principal Investigator
QA  Quality Assurance
RMSE  Residual Mean Square Error
SAE  Serious adverse event
SC  Subcutaneous
SOE  Schedule of events
SOP  Standard operating procedure
T1D  Type 1 diabetes, previously known as insulin-dependent diabetes mellitus
Tregs  Regulatory T cells
ZnT8  Zinc Transporter 8
TABLE OF CONTENTS

1. INTRODUCTION .............................................................................................................. 7
   1.1. Study Overview........................................................................................................... 7

2. BACKGROUND AND RATIONALE FOR THE PROPOSED TRIAL ....................... 12
   2.1. Type 1 diabetes........................................................................................................ 12
   2.2. Omega-3 Fatty Acids .............................................................................................. 13
   2.3. Omega-3 Fatty Acids and Inflammation................................................................. 14
   2.4. Omega-3 Polyunsaturated Fatty Acid Intake and T1D ............................................ 14
   2.5. Vitamin D in T1D .................................................................................................. 16

3. STUDY RATIONALE ...................................................................................................... 17

4. STUDY DESIGN ............................................................................................................ 19
   4.1. Overview ................................................................................................................ 19
   4.2. Objectives ............................................................................................................... 19
       4.2.1. Primary Objective(s) ..................................................................................... 19
       4.2.2. Secondary Objective(s) ............................................................................... 19
   4.3. Investigational Plan ............................................................................................... 20
   4.4. Summary of Inclusion and Exclusion Criteria ....................................................... 20
       4.4.1. Inclusion Criteria ......................................................................................... 20
       4.4.2. Exclusion Criteria ....................................................................................... 21
   4.5. Informed Consent .................................................................................................. 22
   4.6. Description of Treatment Groups ........................................................................... 23
   4.7. Treatment Assignment .......................................................................................... 23
   4.8. Study Assessments ............................................................................................... 23
   4.9. Quality Assurance ............................................................................................... 23
   4.10. Post-treatment Follow-up .................................................................................... 24

5. PATIENT MANAGEMENT ............................................................................................. 24
   5.1. Screening ............................................................................................................... 24
   5.2. Randomization ...................................................................................................... 24
   5.3. Intensive Diabetes Management ............................................................................ 24
   5.4. Administration of Study Drugs .............................................................................. 25
       5.4.1. Omega-3 Fatty Acids ..................................................................................... 25
       5.4.2. Vitamin D ...................................................................................................... 27
       5.4.3. Assessment of Participant Compliance with Study Agent ............................. 29
       5.4.4. Prior and Concomitant Treatments ................................................................. 30
       5.4.5. Removal of Subjects from Therapy or Subject Withdrawal or Early Termination ................................................................................................................. 30
       5.4.6. Discontinuation of study drug(s) in an individual patient . ............................... 30
5.4.7. Re-Entry into Study Treatment ................................................................. 31
5.4.8. Risk to the Subjects .................................................................................. 31
6. STUDY ASSESSMENTS .................................................................................. 32
  6.1. General Assessments .................................................................................. 32
  6.2. Enrollment .................................................................................................. 33
  6.3. Screening (visit -1) and Baseline visits ...................................................... 33
  6.4. Diabetes Management .............................................................................. 33
  6.5. Laboratory Assessments .......................................................................... 34
  6.6. Mechanistic Outcome Assessments .......................................................... 34
  6.7. Metabolic Outcome Assessments ............................................................... 34
  6.8. Visit Windows ........................................................................................... 35
  6.9. Unscheduled visits ................................................................................... 35
  6.10. Sample retention .................................................................................... 35
7. PARTICIPANT SAFETY ................................................................................... 36
  7.1. Staggering Administration ....................................................................... 36
  7.2. Intensive T1D Management ................................................................... 36
  7.3. Safety Monitoring ..................................................................................... 36
  7.4. Ad-hoc DSMB Reviews ......................................................................... 37
  7.5. Temporary Suspension of Enrollment/Drug(s) Dosing or Both ............... 37
  7.6. Stopping rules .......................................................................................... 37
  7.7. Inclusion and exclusion criteria ................................................................. Error! Bookmark not defined.
  7.8. Potential Benefits ..................................................................................... 38
  7.9. Pregnancy ................................................................................................ 38
  7.10. Protecting Against or Minimizing Potential Treatment Risks ............... 38
  7.11. Supplement - Drug Interaction ............................................................... 39
8. ADVERSE EVENT REPORTING AND SAFETY MONITORING ............... 40
  8.1. Adverse Event Definition ......................................................................... 40
    8.1.1. Adverse Event (AE) ........................................................................... 40
    8.1.2. Serious Adverse Event .................................................................... 41
    8.1.3. Unexpected Adverse Event ............................................................... 41
    8.1.4. Grading Event Severity .................................................................... 41
    8.1.5. Evaluation of Adverse events ............................................................ 42
    8.1.6. Adverse Event Reporting and Monitoring ....................................... 42
    8.1.7. Recording Adverse Events ................................................................. 43
    8.1.8. Adverse Events Requiring Expedited Reporting ............................. 44
    8.1.9. Special Reporting Situations ............................................................... 44
    8.1.10. Laboratory Test Result Abnormalities ........................................... 44
8.1.11. Pregnancy .......................................................... 44
8.1.12. Overdose .......................................................... 45
8.1.13. Other Safety Considerations ...................................... 45

9. DATA QUALITY ASSURANCE ........................................... 45
9.1. Data Collection, Monitoring, and Transfer .................................. 45
9.2. Quality Control and Quality Assurance .................................... 46

10. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN .......... 46
10.1. Overview .................................................................. 46
10.2. Endpoints/Outcomes ..................................................... 46
10.3. Measures to Minimize Bias .............................................. 47
10.4. Analysis Plan ............................................................ 47
   10.4.1. Analysis Populations .............................................. 47
   10.4.2. Primary Analysis of Primary Endpoint(s)/Outcome(s) ........ 47
   10.4.3. Supportive Analyses of the Primary Endpoint(s)/Outcome(s) .. 47
   10.4.4. Descriptive Analyses ............................................. 48
10.5. Interim Analyses ........................................................ 48
   10.5.1. Interim Analysis of Efficacy Data ................................ 48
   10.5.2. Interim Analysis of Safety Data .................................. 48
   10.5.3. Futility Analysis .................................................. 49
10.6. Statistical Hypotheses ................................................... 49
10.7. Sample Size Considerations ............................................ 49

11. ETHICAL CONSIDERATIONS & COMPLIANCE WITH GOOD CLINICAL PRACTICE. 50
11.1. Statement of Compliance ............................................... 50
11.2. Informed Consent ....................................................... 50
11.3. Study Subject Confidentiality .......................................... 50

12. STUDY ADMINISTRATION .............................................. 51
12.1. Groups and Committees ................................................ 51
   12.1.1. Protocol Development Committee ................................ 51
   12.1.2. Clinical Site ....................................................... 51
   12.1.3. Medical Monitor for the Clinical Protocol ....................... 51
   12.1.4. Clinical Site Monitoring .......................................... 52
   12.1.5. Data and Safety Monitoring Board (DSMB) .................... 52
   12.1.6. DRI Office of Regulatory Support ................................ 52
   12.1.7. Human Subjects Research Office & Institutional Review Boards (HSRO & IRB) .... 52
   12.1.8. Clinical Research Centers ........................................ 52
   12.1.9. Investigational Drug Services (Research Pharmacy) ......... 53
   12.1.10. Core Laboratories ............................................... 53
12.2. Preservation of the Integrity of the Study .............................. 53
12.3. Participant Reimbursement and Compensation ....................... 53

13. STUDY TIMELINE ........................................................ 53
1. INTRODUCTION

1.1. Study Overview

Title: A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol Supplementation in Type 1 Diabetes

Acronym: POSEIDON study: Pilot study of omega-3 and vitamin D high doses in T1D

Conducted By: Diabetes Research Institute

Study Phase: Phase I/IIa

Accrual Objective: 56 subjects over three years

Study Design: The study is a two-arm, open label, randomized trial. All groups will receive standard intensive diabetes treatment with insulin and dietary management. There will be four groups of participants in this study.

<table>
<thead>
<tr>
<th>Group</th>
<th>Subject population</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Fourteen (14) adults (18-65 years) of established T1D of more than 6 months duration (&gt;180 days) and up to 10 years</td>
</tr>
<tr>
<td>II</td>
<td>Fourteen (14) adults (18-65 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days)</td>
</tr>
<tr>
<td>III</td>
<td>Fourteen (14) children (6-17 years) of established T1D of more than 6 months duration (&gt;180 days) and up to 10 years</td>
</tr>
<tr>
<td>IV</td>
<td>Fourteen (14) children (6-17 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days)</td>
</tr>
</tbody>
</table>

Participants in each group will be randomly assigned in a 1:1 ratio to receive either one year of high dose Omega-3 fatty acids and Vitamin D combination (Arm A) or Vitamin D alone (Arm B). Both arms will receive Vitamin D supplementation.

*Table 1. This table represents supplements used in the study, their doses, routes of administrations and description of two arms*

<table>
<thead>
<tr>
<th>Drugs with route of administration</th>
<th>Dose</th>
<th>Arm A</th>
<th>Arm B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultra-refined omega-3 EPA/DHA concentrate in Liquid or</td>
<td>Based on the body weight of the participant</td>
<td>Three times daily orally</td>
<td></td>
</tr>
</tbody>
</table>

Initial Dose:
<table>
<thead>
<tr>
<th>Capsule formulations</th>
<th>150 mg of EPA+DHA per Kg body weight.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZoneLabs® OmegaRx®2 Fish Oil – Liquid; containing 3375 mg EPA+DHA [2250 mg EPA and 1125 mg DHA] in 5 mL</td>
<td>Maintainance Dose: Dose will be adjusted to maintain a target AA/EPA ratio of 1.5-3.0. AA/EPA ratios will be monitored monthly until achieving target levels and as clinically indicated thereafter.</td>
</tr>
<tr>
<td>Of note, each 1 mL of OmegaRx®2 contains 675 mg of EPA+DHA.</td>
<td>It is 150 mg of combined EPA and DHA per kg body weight to be given either as a single or divided into smaller doses through the day.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vitamin-D 25OH (Cholecalciferol)</th>
<th>Based on the Vitamin D level and age of the participant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily orally</td>
<td>Daily orally</td>
</tr>
<tr>
<td>For levels 30–39 ng/ml:</td>
<td></td>
</tr>
<tr>
<td>Age ≤10 years give 500 IU daily</td>
<td></td>
</tr>
<tr>
<td>Age &gt;10 years give 1000 IU daily</td>
<td></td>
</tr>
<tr>
<td>For levels 20–29 ng/ml</td>
<td></td>
</tr>
<tr>
<td>50,000 IU weekly for 2 months and then:</td>
<td></td>
</tr>
<tr>
<td>Age ≤10 years give 1000 IU daily</td>
<td></td>
</tr>
<tr>
<td>Age &gt;10 years give 2000 IU daily</td>
<td></td>
</tr>
<tr>
<td>For levels &lt; 20 ng/ml</td>
<td></td>
</tr>
</tbody>
</table>
| Treatment Description | 50,000 IU weekly for 6 months and then:  
| | Age ≤10 years, give 1000 IU daily  
| | Age >10 years, give 2000 IU daily  
| | Dose will be adjusted and monitored every four months until achieving target levels and as clinically indicated thereafter. |

| Study Duration | Subjects will be randomized to one of the two arms. The treatment arm A includes Omega-3 Fatty Acids and Vitamin D. The subjects randomized in Arm B (control group) will receive only Vitamin D supplement. The treatment assignment will be conducted in a open label fashion. |

| Objective | All subjects will be treated and followed for one year, and will be followed for up to one additional year beyond the period of treatment. Enrollment is expected to occur over three years. |

| Objective | Conduct a clinical intervention study to assess, in participants with established T1D (>6 months and up to 10 years after diagnosis) or with new onset T1D (≤6 months from diagnosis):  
| | Primary outcome: Stimulated (90 minute sample of a MMTT) C-peptide at the 1 year visit greater or equal to baseline level.  
| | Secondary objectives: Stimulated C-peptide area under the curve (AUC) during a 4-hour MMTT greater or equal to baseline level, at the 1 year visit.  
| | Reduction in HbA1c at the one year visit compared to baseline.  
| | Reduction in insulin requirement at the 1 year visit compared to baseline.  
| | Incidence of adverse events (AE) comparable to general diabetes population. |

| Inclusion Criteria | Patients must meet all of the following criteria to be eligible to participate in this study:  
| | Subject must be able to understand and provide informed consent.  
| | Males and females, 6-17 years for children and 18-65 years of age for adult group.  
| | For new onset T1D - from onset to 6 months (180 days) post diagnosis at the time of randomization.  
| | For established T1D – At least 6 months and up to 10 years from the diagnosis at the time of randomization. |
Exclusion Criteria

- Affected by T1D, according to ADA standard criteria, and confirmed by positivity of at least one T1D-associated autoantibody, to GAD65, IA-2, ZnT8, or insulin autoantibody (if patient has been treated with insulin for less than 2 weeks).
- T1D must be treated with insulin injections.
- Stimulated C-peptide peak level, at the baseline 1 visit MMTT, ≥ 0.2 ng/ml.
- Female subjects of childbearing potential must have a negative pregnancy test upon study entry.
- Female (and male) subjects with reproductive potential must agree to use two FDA approved methods of birth control for the entire duration of the study.
- Adequate venous access to support study required blood draws.

Patients must not meet any of the following criteria to be eligible to participate:

- Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
- BMI>30 kg/m².
- Contra-indications to any of the drugs used in the trial (as per package insert, e.g., knowledge of hypersensitivity to drugs or its excipients).
- Uncompensated heart failure, fluid overload, myocardial infarction or liver disease or severe impairment of a vital organ within the last 6 weeks before enrollment.
- Any of the following laboratory findings indicating hemoglobin <10.0 g/dL; leukocytes <3,000/μL; neutrophils <1,500/μL; lymphocytes <800/μL; platelets <100,000/μL.
- Any sign or diagnosis of significant chronic active infection (e.g., hepatitis, tuberculosis, EBV, or CMV), or screening laboratory evidence consistent with a significant chronic active infection (such as positive for HIV, IGRA test for TB, or hepatitis B-C).
- Ongoing acute infections, e.g., acute respiratory tract, urinary tract, or gastrointestinal tract infections.
- Ongoing or anticipated use of diabetes medications other than insulin.
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening.
- Current or prior use of immunomodulators or systemic steroids in the last 2 months that could potentially affect diabetes or immunologic status.
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within 6 weeks of randomization.
- Use of investigational drugs within 3 months of participation.
- Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization.
- History or diagnosis of malignancy. Any history of gastroparesis or other severe gastrointestinal disease, pancreatitis, thyroid nodules or malignancy with the exception of a history of localized basal cell carcinoma.
- Presence of an allograft.
- AST, ALT or Alkaline Phosphatase >2 times upper limit of normal or total bilirubin >1.5 times upper limit of normal.
- Current, diagnosed, mental illness or current, diagnosed or self-reported drug or alcohol abuse; or any situation that, in the opinion of the investigator, would interfere with the participant’s ability to comply with study requirements.
- Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of contraception, for the entire duration of the study.
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant’s ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
2. BACKGROUND AND RATIONALE FOR THE PROPOSED TRIAL

2.1. Type 1 diabetes

Type 1 diabetes (T1D) is a chronic autoimmune disease leading to the selective destruction of insulin producing beta cells within the pancreatic islets. Autoreactive T cells and abnormalities in immune regulation, especially in regulatory T cells (Treg cells), play a key role in disease development (Pugliese, 2014). In the U.S. alone, approximately 1.3 million people, especially children and adolescents, suffer from T1D; the disease incidence is increasing in many countries (Cizza et al, 2012; Forlenza & Rewers, 2011; Pettitt et al, 2013; Vehik & Dabelea, 2011). Chronic autoimmune T cell responses against pancreatic β-cells are considered the primary cause of T1D, leading to loss of β-cell mass and insulin secretion and in turn life-long dependence on insulin injections (Coppieters et al, 2012; Roep & Peakman, 2012). The disease severely impacts quality of life and confers risk for both acute and chronic complications linked to significant morbidity and mortality, such as end stage renal disease, blindness, cardiovascular disease, diabetic ketoacidosis and hypoglycemia (Cengiz et al, 2013; Nathan, 2014). The economic burden caused by T1D amounts to approximately $14.4 billion in medical costs and lost income (Tao et al, 2010).

The discovery of insulin in 1922 dramatically changed the prognosis of T1D. It was the first effective therapy, which converted a fatal condition into a chronic disease. However, the prolonged life expectancy allows time for the development of long-term complications, e.g. retinopathy, neuropathy, nephropathy and vasculopathy, which are largely related to the imperfect degree of metabolic control afforded by insulin therapy. The “Diabetes Control and Complications Trial” showed those intensive insulin regimens that achieve tight blood glucose control reduced the risk of complications in T1D (Nathan, 2014). Yet this level of tight control is difficult to achieve for many patients, despite many advances in insulin therapy and blood glucose monitoring, and it bears significant risk of hypoglycemia (Steffes et al, 2003; Zinman, 1998).

T1D requires lifelong therapy with insulin injections, multiple times daily. Despite much progress in insulin preparations, insulin therapy is inadequate in most patients (Hirsch & Skyler, 2000; Pouwer & Hermanns, 2009). Insulin dosing largely remains an empiric decision and is prone to error, which in turn can lead to severe, life-threatening hyperglycemia or hypoglycemia. Blood glucose monitoring is required to adjust insulin doses. Even patients who employ frequent finger-stick blood glucose monitoring fail to maintain strict glycemic control within the ADA-specified optimal range 70% of the time (Bode et al, 2005). The use of wearable Continuous Glucose Monitoring (CGM) devices and insulin pumps represent a step forward, yet they fail to restore normal glucose metabolism and may still be hyperglycemic almost 30% of the time (Bode et al, 2005). Patients using CGM may be hypoglycemic approximately 8% of each day, with a propensity for hypoglycemic events to occur at night (Bode et al, 2005), when hypoglycemia can more likely go unnoticed and can be therefore more dangerous. In some cases, severe hypoglycemic events, i.e., those requiring the aid of another person to administer carbohydrates, glucagon, or other resuscitative assistance, can lead to seizures, unconsciousness, coma, and death. Frequent hypoglycemia lead to hypoglycemia unawareness, which increases their risk of severe hypoglycemia and serious sequelae by at least 6-fold (Seaquist et al, 2013). Moreover, severe and multiple hypoglycemic episodes are associated with increased risk of death lead to death (Weinstock et al, 2013).
Transplantation can reverse diabetes by replacing the lost beta cell mass. Both transplantation of whole pancreas and transplantation of purified pancreatic islets are possible and can lead to reversal of the diabetic state (Bruni et al, 2014; Mineo et al, 2009; Watson, 2015; White et al, 2009). Both procedures have improved over time, but many more whole pancreas transplants have been performed compared to islet transplants. Although it requires invasive surgery and has a higher risk of perioperative mortality and morbidity, pancreas transplantation is correlated with longer graft survival and function than islet transplantation. Pancreas transplantation is particularly beneficial for patients with T1D and end stage renal disease (ESRD), in whom transplantation of pancreas and kidney restores both insulin secretion and renal function for several years. However, in all forms of transplantation, patients are required to be treated with chronic immunosuppression to prevent rejection, which is associated with well-known side effects and health risks that also limit applicability of transplantation to younger patients, representing the predominant portion of newly diagnosed patients. Moreover, our own studies have shown that approximately 5-6% of pancreas transplant recipients may develop recurrence of type 1 diabetes in the transplanted pancreas, despite immunosuppression that prevents rejection (Burke et al, 2011; Vendrame et al, 2010).

There is much hope that stem cells based approaches may provide new sources of beta cells, and yet it will be critical to define immunomodulation protocols that can control islet autoimmunity and prevent rejection of transplanted cells, recurrence of disease, and as well help patients preserve insulin secretion from the residual beta cell mass at diagnosis (Orlando et al, 2014). Thus, there is a need to develop new therapies to interdict islet autoimmunity, to prevent, treat and cure T1D. Even a partial level of insulin secretion affords protection from chronic complications (Steffes et al, 2003), hypoglycemia and diabetic ketoacidosis (Ludvigsson, 2013), which can all lead to death (Realsen et al, 2012; Rosenbloom, 2010; Weinstock et al, 2013).

2.2. Omega-3 Fatty Acids

The human body can make most of the types of fats it needs from other fats or raw materials. That isn’t the case for omega-3 fatty acids (also called omega-3 fats and n-3 fats). These are essential fats—the body can’t make them but must get them from food. Foods high in Omega-3 include fish, vegetable oils, nuts (especially walnuts), flax seeds, flaxseed oil, and leafy vegetables.

The omega-3 fats are special for many reasons. They are an integral part of cell membranes throughout the body and affect the function of the cell receptors in these membranes. They provide the starting point for making hormones that regulate blood clotting, contraction and relaxation of artery walls, and inflammation. They also bind to receptors in cells that regulate genetic function. Likely due to these effects, omega-3 fats have been shown to help prevent heart disease and stroke, may help control lupus, eczema, and rheumatoid arthritis, and may play protective roles in cancer and other conditions.

Omega-3 fats are a key family of polyunsaturated fats. There are three main omega-3s: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) come mainly from fish, so they are sometimes called marine omega-3s.

Alpha-linolenic acid (ALA), the most common omega-3 fatty acid in most Western diets, is found in vegetable oils and nuts (especially walnuts), flax seeds and flaxseed oil, leafy vegetables, and some animal fat, especially in grass-fed animals. The human body generally uses ALA for energy, and conversion into EPA and DHA is very limited.
Cell membranes require unsaturated fatty acids to maintain structure and function. Desaturase enzymes present in mammals add a double bond to form a monounsaturated fatty acid, oleic acid (18:1 n9), from stearate. Animals, unlike plants, can insert additional double bonds to create two classes of polyunsaturated fatty acids (PUFA), n-6 and n3. Plants convert oleic acid to linoleic acid (LA) (18:2 n-6) and desaturation of oleic produces α-linolenic (ALA) (18:3 n-3). Marine algae also produce EPA (20:5 n-3) and DHA (22:6 n-3) that are eventually transferred through the food chain to fish whose oils are high in ω-3 fatty acids. Mammals cannot synthesize LA (the predominant PUFA in Western diets) and ALA; therefore these fatty acids are “essential” and must be ingested. Mammals, unlike plants, cannot interconvert n9, n6 and n3 fatty acids, but do further convert LA to other n-6 fatty acids, (e.g., arachidonic acid (20:4 n-6)) and ALA to n-3 EPA and DHA.

2.3. Omega-3 Fatty Acids and Inflammation
Omega-3 fatty acids reduce inflammatory cytokines and inflammatory prostaglandins, both of which may be related to the initial inflammation in islet cells. The mechanism of omega-3 fatty acids reducing inflammation has been shown secondary to limiting proinflammatory cytokines and the activity of the PGS2 enzyme (Litherland et al., 1999). Therefore, it was proposed that the increased PGS2 expression and cytokine production observed in children at high-risk for developing T1D may be reduced through omega-3 fatty acid supplementation (Litherland et al., 2003). Arachidonic acid (AA), DHA, and eicosapentaenoic acid (EPA) inhibit PGS2 with similar potency, which is greater than that seen with other fatty acid analogues. Endres et al (1989) found that the syntheses of interleukin-1 (IL-1alpha and IL-1 beta) and of tumor necrosis factor (TNF), cytokines with potent inflammatory activities, were reduced by dietary supplementation with n-3 fatty acids. The anti-inflammatory effect of these n-3 fatty acids may be mediated in part by their inhibitory effect on the production of IL-1 and TNF.

2.4. Omega-3 Polyunsaturated Fatty Acid Intake and T1D
The incidence of T1D is increasing, particularly in very young children. We hypothesize that the lack of omega-3 fatty acids in the diet has contributed to this increase. These are essential fats—the body can’t make them but must get them from food. Just 100 years ago, consumption of n-6 to n-3 fatty acids in the diet was at a 1:1 ratio. In 1999, the ratio was reported to be approximately 30:1 (Simopoulos AP, 1999). Because of the warnings to eliminate fish during pregnancy, the ratio is likely even greater during pregnancy. This results in increased production of inflammatory prostaglandins and cytokines during this critical time of fetal development. This trend towards substitution of the inflammation producing n-6 fatty acids at the expense of the anti-inflammatory n-3 fatty acids may be contributing to the increase in the number of cases of T1D diagnosed each year.

More direct evidence also suggests a relationship between omega-3 fatty acids and T1D. Decsi and colleagues demonstrated that 40 children with T1D had significantly lower DHA levels and a lower n-3: n-6 ratio than the control children, which may partially explain the altered prostanoid and inflammatory cytokine production. They conclude that the reduced availability of long-chain polyunsaturates in children with T1D suggests the need for enhanced dietary supply (Decsi et al., 2002).

Observations have been made that children who have received omega-3 fatty acid supplementation have a lower risk of T1D. Children born to women from Norwegian fishing villages had a significantly decreased risk of getting diabetes compared with the children of
women who lived in cities away from the coast (Joner G. 1992). Using a case-control design, Stene et al. found that cod liver oil, either taken by the mother during pregnancy or by the child during the first year of life, was associated with a decreased risk of developing T1D (Stene et al., 2000). They concluded that either the vitamin D or the eicosapentaenoic acid (EPA) or the docosahexaenoic acid (DHA) or all three cod liver oil components have protective effects against developing T1D. In a larger and more recent study, Stene and colleagues in Norway found that supplementation with cod liver oil during the first year of life was associated with a significantly lower risk of T1D before age 15, odds ratio (OR) of 0.7 (p<0.001) (Stene and Joner, 2003). This is consistent with the hypothesis that omega-3 fatty acids (or vitamin D) have a protective effect. It now appears that the protective effect may occur during pregnancy or during infancy or both.

Figure 1 EPA and AA compete for COX and LOX enzymes

T1D is an autoimmune disease that is characterized by the destruction of insulin-producing beta cells in the pancreatic islets. Although it is not yet known what initiates the autoimmune process, it is likely that both genetic background and environmental factors contribute to the disease process. Dietary factors have been implicated in the etiology of type 1 diabetes as well as in initiating the autoimmune process that leads to clinical disease. A case-control study from Norway (Stene and Joner, 2003) reported that children with diabetes were less likely to have been given cod liver oil during infancy than children without diabetes. Given that cod liver oil contains both vitamin D and the marine omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), it was not clear whether the protective factor in cod liver oil was the vitamin D, the marine fatty acids, or both.

Although two studies reported that children with diabetes were less likely to have taken vitamin D supplements in infancy than children without diabetes (EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for type I insulin-dependent diabetes mellitus, and Hypponen et al 2001), similar investigations focusing on the intake of marine omega-3 fatty acids have not been conducted to resolve this important question. The clinical phase of type 1 diabetes, where hyperglycemia manifests, is preceded by an asymptomatic period that varies in duration, ranging from a few months to several years, in which autoantibodies to the beta cells and their antigens are
detectable in the blood. Persistent positivity of these autoantibodies confers a high risk of subsequent development of type 1 diabetes in relatives of those individuals with diabetes and in the general population. Because autoantibodies appear before clinical diabetes, examination of risk factors for the appearance of these autoantibodies would yield important clues regarding the early pathogenic events leading to autoimmunity, and perhaps the pathogenesis of type 1 diabetes itself.

Studies suggest that macrophage infiltration and inflammatory cytokine production are early events in the pathogenesis of type 1 diabetes (Chase et al., 2004; Jansen et al., 1994; Green and Flavell, 1994; Dahlen et al., 1998). Therefore, identifying factors that either promote or block the impact of these early pathogenic inflammatory events may be key to promoting or inhibiting the development of type 1 diabetes. Several studies have demonstrated a strong effect of omega-3 fatty acids on inflammatory responses in animals and humans (Endres et al., 1989; Calder, 2001; De Caterina et al., 2004). A relative deficiency of omega-3 fatty acids, a characteristic of many Western diets, may predispose to heightened inflammatory reactions and thus increase the risk for autoimmune diseases, such as type 1 diabetes. Alpha-linolenic acid (ALA) is the principal omega-3 fatty acid in Western diets and is found in the green leaves of plants, and also in selected seeds, nuts, and legumes (eg, flax, canola, walnuts, and soy). Alpha-linolenic acid may serve in a limited capacity as a precursor for EPA and DHA, 2 omega-3 fatty acids that are primarily obtained from fish. Linoleic acid is the most abundant omega-6 fatty acid in the diet and is found primarily in nut, seed, and vegetable oils. Arachidonic acid is an omega-6 fatty acid that can be derived from linoleic acid and is also found in meat and poultry. Because ALA and linoleic acid compete for key enzymes involved in fatty acid metabolism and conversion to either pro-inflammatory or anti-inflammatory eicosanoids, it is important to examine the effects of omega-3 and omega-6 fatty acid intakes together.

2.5. Vitamin D in T1D
As noted above, the observation that cod liver oil was associated with lower risk of T1D suggests the possibility of a synergistic effect of both of the components of cod liver oil (DHA and vitamin D) (Stene and Joner, 2003). A large retrospective cohort study demonstrated an association between vitamin D supplementation in the first year of life and a lower risk of T1D [24]. This association was also demonstrated in a prospective study in which infants received vitamin D supplementation (Stene et al., 2000; Stene and Joner, 2003). The mechanism may be related to the immunosuppressive properties of Vitamin D or possibly a direct effect on islet cell insulin secretion. Vitamin D receptor (VDR) gene polymorphisms have recently been associated with susceptibility to T1D in humans (Alician et al., 2009; Lowe et al., 2007). Interestingly, Stene et al (2000) found an indication for a protective effect with certain polymorphisms, but this was strongest for children who took cod liver oil during the first year of life.

Serum 25-hydroxyvitamin D (25-OHD) concentrations are largely determined by environmental factors, mainly through vitamin D intake and ultraviolet exposure. The sun is the primary source of vitamin D, which is synthesized endogenously in skin to produce cholecalciferol (vitamin D3), although a small proportion (<20%) of vitamin D comes through diet from a limited range of foods (in the form of ergocalciferol [vitamin D2] and vitamin D3) (Holick 2006). The main marker of vitamin D status is the metabolite 25-OHD, which is synthesized in the liver (Chiu et al., 2004; Norman et al., 1980).
A relationship between type 1 diabetes mellitus and vitamin D deficiency has been reported (Luong et al., 2005; Mathieu et al., 2005). The prevalence of vitamin D deficiency in patients with type 1 diabetes was 15% to 90.6% (Greer and Rogers, 2007; Svoren et al., 2009; Bener et al., 2009). There is evidence that vitamin D is important in the prevention of islet cell death and might be useful in improving the survival of islet cell grafts, and it improves the production of insulin. Low vitamin D levels were shown to have a negative effect on beta-cell function (Chiu et al., 2004; Norman et al., 1980). Regular doses of vitamin D early in life have been shown to reduce the risk of developing type 1 diabetes (Luong et al., 2005). Vitamin D treatment has also been shown to improve glycemic control and insulin sensitivity in people with type 1 and type 2 diabetes and in normal individuals. Increasing vitamin D levels from 25 to 75 nmol/L results in a 60% improvement in insulin sensitivity. (Chiu et al., 2004; Norman et al., 1980; Borissova et al., 2003; Gedik and Akalin 1986; Schwalfenberg 2008). These effects have been mainly attributed to the immunomodulatory actions of vitamin D (Luong et al., 2005).

Geographic location seems to play a part in the development of type I diabetes with risk increasing as farther from the equator. The location on Earth contributes to the amount of vitamin D the body produces. This observation is suggestive, but not proof, that vitamin D affects the development of type 1 diabetes. Finland, a country that is at latitude far from the tropics, has the highest incidence of type 1 diabetes in the world. In the late 1960s, it was common to supplement an infant’s diet with 2,000 IU vitamin D. When researchers compared the development of type 1 diabetes in people 30 years later based on whether their mothers recalled giving them vitamin D during the first year after birth, they found an 80 percent reduction in the risk of type 1 diabetes later in life. Calcitriol makes insulin-secreting beta cells resistant to immune system attack. The active vitamin appears to reduce the production of cytokines, substances that kill beta cells.

Currently, project NCT03046927 conducted at the University of Massachusetts, Worcester is studying the role of vitamin D supplementation on the honeymoon phase of type 1 diabetes in children who are on standardized insulin treatment. The investigation is based on hypothesis that early intervention with vitamin D lead to significant changes in the approach to the early phase of type 1 diabetes with a strong emphasis on prolonging the honeymoon phase by using vitamin D and maintaining these patients on a standardized insulin regimen. The study rationale also indicates role of vitamin D in reducing the long-term complications of type 1 diabetes.

3. STUDY RATIONALE

The anti-inflammatory properties of omega-3 long-chain polyunsaturated fatty acids (LCPUFA) [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] have been extensively reported in the literature. Derivatives from omega-3 LCPUFA have been associated with marked anti-inflammatory effects whereas arachidonic acid (AA), an omega-6 LCPUFA, is the precursor of eicosanoids associated with pro-inflammatory properties. Thus, a high AA/EPA ratio would suggest that the balance is shifted towards a pro-inflammatory state. Treatment with omega-3 fatty acids aimed at lowering the AA/EPA ratio may then prove to be beneficial particularly in diseases associated with a high inflammatory state. Bioactive metabolites such as resolvins and protectins are derived from omega-3 fatty acids and are postulated to mediate the anti-inflammatory properties of omega-3 fatty acids. These mediators act by several mechanisms including reduction of neutrophil infiltration, attenuation of TNF stimulated NF-κB activation, inhibition of interleukin-1β (IL-1β),
reduction in tumor necrosis factor (TNF) and interferon-\(\gamma\) secretion, inhibition of T-cell migration and regulation of T-cell apoptosis. Notably, IL-\(1\beta\) and TNF have both been implicated in beta-cell death and IFN signatures as well as T cell infiltration of the pancreatic islets have been associated with type 1 diabetes (T1D).

A number of studies suggest that omega-3 fatty acids may be beneficial in T1D:

- Bellenger et al. reported that transgenic fat-1 mice, a model of endogenous omega-3 LCPUFA synthesis, were protected against streptozotocin-induced diabetes. This protection was associated with a reduction in pro-inflammatory cytokines with a concomitant increase in anti-inflammatory cytokines.

- The Diabetes Autoimmunity Study in the Young (DAISY) follows children at high risk for T1D development; in this study, dietary intake of omega-3 fatty acids was associated with a reduced risk of developing islet autoimmunity, especially of developing multiple autoantibodies, which are a strong risk factor for future disease. There was no association with the development of T1D.

- The Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study was a pilot study which evaluated the effect of DHA supplementation on inflammatory cytokine levels in infants at high genetic risk for T1D. Although DHA supplementation of infant diets was found to be safe, inflammatory cytokine production was not consistently reduced. However, the study was not designed to adjust dietary intake of omega-3 fatty acids to target specific AA/EPA ratios and it is unclear whether reaching specific ratios may translate into improved clinical outcomes.

However, in a pilot study of T1D patients with established disease (>4 years duration) omega-3 fatty acids failed to improve glycemic control after 4 weeks of therapy. This may suggest that anti-inflammatory therapies may need to be introduced early in the course of T1D in order to have an impact on prevention of beta-cell loss. In addition, considering that T1D is a chronic autoimmune and inflammatory disease, anti-inflammatory strategies may need to be administered over a prolonged period of time in order to observe a clinical benefit.

The anti-inflammatory properties of vitamin D are well established. In particular, it has been shown that Vitamin D prevents both insulitis and type 1 diabetes mellitus in mouse models of T1D and retrospective studies have shown apparent beneficial effects of vitamin D supplementation in early life on successive lifetime risk of T1DM. Vitamin D has been linked to several immunomodulatory effects. Studies in new onset T1D have shown that treatment with cholecalciferol (vitamin D3) results in both an increase in the percentage and the suppressive capacity of regulatory T-cells. A recent study in adults with vitamin D deficiency showed that daily treatment with 4,000 IU of vitamin D3 significantly reduced CD4+ T-cell activation compared to treatment with 400 units of vitamin D3. However, the role of vitamin D in preservation of beta-cell function in new onset T1D is controversial. Two studies showed no significant effect of therapy with calcitriol (1,25(OH)2D3) whereas one study using 2,000 IU of cholecalciferol daily showed a higher stimulated C-peptide at 18 months compared to placebo. Further studies evaluating the role of vitamin D supplementation in prevention of beta-cell loss at T1D onset are warranted.
Considering the safety profile and anti-inflammatory properties of high dose omega-3 fatty acids combined with Vitamin D supplementation makes this therapy a possible candidate for T1D intervention trials.

4. STUDY DESIGN

4.1. Overview

Based on the findings presented in this document, we propose to test the safety and efficacy of a regimen that combines Omega-3 Fatty Acids and Vitamin D in a design that considers timing and duration of administration in relation to their effects and predicted synergies. These agents may promote sustained immune regulation, reduce inflammation, and provide support for the residual beta cell mass. This integrated therapeutic regimen addresses major pathogenic mechanisms in T1D and thus represents a rational and well supported approach to preserve insulin secretion in T1D. This approach could halt the disease progress, preserve β-cell function and hopefully reduce dose of insulin required to manage T1D. Even partial beta cell function can facilitate disease management, reduce the likelihood of severe hypoglycemia and is associated with reduced risk of chronic complications. We hypothesize that Omega-3 Fatty Acids and Vitamin D, administered to patients with newly or established T1D and residual stimulated C-peptide secretion Will be safe and may preserve insulin secretion;

The safety will be measured by the AE profile. In addition, potential decreases in hypoglycemic events will be evaluated as this may be expected to be one of the clinical indications where combination therapy is likely to exert a clinical benefit. Other measures include the ability of combined supplement therapy to increase insulin production as assessed by serum C-peptide measurements, changes in exogenous insulin dose, and measurements of glycemic control.

The study endpoints vary between the two arms and include safety, tolerability, and efficacy. Safety endpoints include AEs over one year of treatment and an additional one year of follow-up (total two years). Efficacy endpoints include the ability of combining supplement products to produce insulin, assessed by serum C-peptide measurements following a Mixed Meal Tolerance Test (MMTT), changes in recorded exogenous insulin dose and other measures of glycemic control.

4.2. Objectives

4.2.1. Primary Objective(s)

- Stimulated (90 minute sample of a MMTT) C-peptide at the 1 year visit greater or equal to baseline level.

4.2.2. Secondary Objective(s)

- Stimulated C-peptide area under the curve (AUC) during a 4-hour MMTT greater or equal to baseline level, at the 1 year visit.
- Reduction in HbA1c at the one year visit compared to baseline.
- Reduction in insulin requirement at the 1 year visit compared to baseline.
- Incidence of adverse events (AE) comparable to general diabetes population.
4.3. **Investigational Plan**

This is a randomized, open-label, parallel-group, pilot phase I/IIa clinical study. Approximately 56 subjects will be randomly assigned to receive either Omega-3 Fatty Acids and Vitamin D combination or Vitamin D alone. All subjects will be given Vitamin D supplement. Patients to be included in this study are those diagnosed with new onset T1D (diagnosed within the last 180 days) or with established T1D (more than 6 months).

Participation for each subject will last approximately 2 years. Potential participants will have two screening visits to review their overall health, measure diabetes T1D-associated autoantibodies and perform a MMTT, which will also serve as the baseline MMTT. Eligible subjects will be invited to participate in the intervention trial for one year, and then followed for a second year to monitor safety and whether any potential therapeutic benefit, whether metabolic, endocrine, and/or immunological, persist after the therapy has been stopped.

We will evaluate beta cell function by examining C-peptide responses during a MMTT, and determine beta-cell sensitivity to glucose, insulin sensitivity, and insulin secretion from glucose and C-peptide data obtained during the MMTTs using the Mari model (Mari & Ferrannini, 2008). It is documented that beta cells in T1D are “blind” to glucose by showing reduced beta cell sensitivity to glucose using the Mari model in relatives at risk of T1D (Ferrannini et al, 2010). The extent to which this may account for reduced beta cell function, and whether this is to any degree reversible, is unknown. Thus, we will characterize beta cell function in response to Omega-3 Fatty Acids and Vitamin D by measuring insulin secretion during a 4 hour MMTT, and using the Mari model to calculate beta cell sensitivity to glucose and insulin sensitivity/resistance.

4.4. **Summary of Inclusion and Exclusion Criteria**

This study can fulfill its objectives only if appropriate patients are enrolled. The following eligibility criteria are designed to select patients for whom protocol treatment is considered appropriate. All relevant medical and non-medical conditions will be taken into consideration when deciding whether this protocol is suitable for a particular participant.

We will enroll T1D patients of both genders, 6-65 years -old, to examine the Omega-3 Fatty Acids and Vitamin D supplements covering as much of the age spectrum of the disease in both established as well as new onset T1D patients. There will be no restriction on race and ethnicity. However, T1D is more prevalent in populations of European descent, and enrollment will likely reflect disease prevalence in the Miami area, where the population is diverse and enriched in ethnicities from Latin America. Subjects who fulfill the following eligibility criteria will be recruited regardless of their race or gender.

4.4.1. **Inclusion Criteria**

Patients **must meet all** of the following criteria to be eligible to participate in this study:

1. Subjects or their parents if under 18 years old must be able to understand and provide informed consent.
2. Males and females, 6-65 years of age.
3. For pediatric population, Tanner stage: I-V

4. Subject has to provide evidence of detectable fasting c-peptide and its corresponding glucose (Glucose needs to be within 70-200 mg/dl) within the last 6 months prior to enrollment from local provider.

5. New onset T1D for no longer than 180 days at the time of randomization where Stimulated C-peptide peak level ≥0.2 ng/ml at the baseline 1 visit MMTT.

6. Established T1D subjects must have the T1D diagnosis for more than 180 days and up to 10 years of T1D duration at the time of randomization and Stimulated C-peptide peak level ≥0.2 ng/ml at the baseline 1 visit MMTT.

7. Affected by T1D, according to ADA standard criteria, and confirmed by positivity of at least one T1D-associated autoantibody, to GAD65, IA-2, ZnT8, or insulin autoantibodies (if patient has been treated with insulin for less than 2 weeks).

8. Being on insulin therapy.

9. Female subjects of childbearing potential must have a negative pregnancy test upon study entry.

10. Female (and male) subjects with reproductive potential must agree to use two FDA approved methods of birth control for the entire duration of the study.

11. Adequate venous access to support study required blood draws.

4.4.2. Exclusion Criteria

Potential participants must not meet any of the following exclusion criteria:

1. Inability or unwillingness of a participant or their parents to give written informed consent or comply with study protocol.

2. BMI>30 Kg/m².

3. Contra-indications to Omega-3 Fatty Acids and/or Vitamin-D (e.g., knowledge of hypersensitivity to drugs or its excipients, allergies with fish or shellfish etc.).

4. Uncompensated heart failure, fluid overload, myocardial infarction or liver disease or severe impairment of a vital organ within the last 6 weeks before enrollment.

5. Any sign or diagnosis of significant chronic active infection (e.g., hepatitis, tuberculosis, EBV, or CMV), or screening laboratory evidence consistent with a significant chronic active infection (such as positive for HIV, IGRA test for TB, or hepatitis B-C).

6. Ongoing acute infections, e.g., acute respiratory tract urinary tract, or gastrointestinal tract infections.

7. Subjects on weight altering medications, such as orlistat.

8. Subjects with eating disorders

9. Ongoing or anticipated use of diabetes medications other than insulin.
10. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening.

11. Current or prior use of immunomodulators or systemic steroids in the last 2 months that could potentially affect diabetes or immunologic status.

12. People who chronically take drugs that affect bleeding time, such as anticoagulants ("blood thinners") or nonsteroidal anti-inflammatory drugs (NSAIDs), will not qualify to enroll in the study.

13. Recent recipient of any licensed or investigational live attenuated vaccine(s) within 6 weeks of randomization.

14. Use of investigational drugs within 4 months of participation.

15. Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization.

16. History or diagnosis of malignancy. Any history of gastroparesis or other severe gastrointestinal disease, pancreatitis, thyroid nodules or malignancy with the exception of a history of localized basal cell carcinoma. There is conflicting evidence about whether omega-3 fatty acids found in seafood and fish oil might increase the risk of prostate cancer. Until additional research on the association of omega-3 consumption and prostate cancer risk is conducted, subjects with family history of prostate cancer in a first-degree relative will be excluded from the study.

17. Presence of an allograft.

18. AST, ALT or Alkaline Phosphatase >2 times upper limit of normal or total bilirubin >1.5 times upper limit of normal.

19. Current, diagnosed, mental illness or current, diagnosed or self-reported drug or alcohol abuse; or any situation that, in the opinion of the investigator, would interfere with the participant’s ability to comply with study requirements.

20. Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of contraception, for the entire duration of the study.

21. Past or current medical problems, or findings from physical examination, or laboratory testing, that are not listed above which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant’s ability to comply with study requirements or that may impact the quality or interpretation of the data obtained.

22. All patients who have coagulation, bleeding, or blood disorders will be excluded due to the effect of high dose of Omega 3 Fatty Acids on coagulation and bleeding process.

4.5. Informed Consent
The process of assuring that individuals are making an informed decision about participating in this study includes both verbal and written communication. The consent form will be reviewed with participants and the participant will be given time to review the written consent form and ask questions. The participant will be given a copy of their signed consent forms.

Participants will also be informed about the common adverse effects of study drugs and it will be recommended that they stop eating once they feel satiety to decrease the risk of nausea and vomiting during the treatment period. Study subjects will receive standard medical care from their endocrinologist, but the study team will closely monitor the patients to assess adverse events. At these phone or email contacts and at the study visits, the frequency of hypoglycemia will be documented. Hypoglycemia will be assessed following consensus definition (Agiostratidou, 2017). Three levels of hypoglycemia will be recorded. Level 1: glucose < 70 mg/dl (3.9 mmol/l) and glucose ≥ 54 (mg/dl) (3.0 mmol/l). Level 2: glucose < 54 mg/dl (3.0 mmol/l) and Level 3: a severe event characterized by altered mental and/or physical status requiring assistance.

4.6. Description of Treatment Groups

This open label protocol will enroll a total of 56 participants who will be randomly assigned (1:1) to the following groups:

- 28 participants will be assigned to receive Omega-3 Fatty Acids and Vitamin D combination following randomization, and then will be followed for an additional year.
- 28 participants will receive only Vitamin D.

4.7. Treatment Assignment

Eligible participants who have provided written informed consent will be randomized to one of the treatment groups. The participant, the clinical investigator and clinical personnel will be known to the treatment assignment.

4.8. Study Assessments

During the course of the study, participants will frequently undergo assessments of their insulin production, immunologic status, overall health and well-being and diabetes care (see schedule of assessments in Appendix 1). The participant’s insulin production will be assessed by C-peptide measurements during mixed meal glucose tolerance tests (MMTT) conducted as per the study schedule. The MMTT will consist of a standard liquid meal (Boost Plus®, Nestlé HealthScience) at a dose of 6 mL/Kg to a maximum of 360 mL. The participant’s diabetes control will be evaluated by measuring glycosylated hemoglobin (HbA1c) every four months.

Remaining samples will be stored in the Diabetes Research Institute for future analysis. Samples will be stored only with the participant’s permission. Participants who decline consent for storage of remaining samples will still be eligible to participate in this study.

4.9. Quality Assurance
During the study, duplicate collections of blood samples for assays will be obtained in a small sample of subjects for the purpose of external quality surveillance of the performance of the laboratories.

4.10. Post-treatment Follow-up

All subjects will be treated with supplement combination or vitamin D alone over a one year period. Subjects will also be asked to undergo additional follow-up post-treatment for up to one year with a visit every 4 months.

5. PATIENT MANAGEMENT

5.1. Screening

After informed consent, subjects will undergo assessments to determine if they meet eligibility criteria. Documentation of the subjects understanding of the risks and benefits of the study will also be discussed during the informed consent process.

5.2. Randomization

Individuals complying with all inclusion and exclusion criteria and consenting to study participation will be randomized to one of the two groups in 1:1 ratio. The biostatistician will produce the randomization code and scheme through a computer generated process. Prior to randomization, the study coordinator at the site will complete a Pre-Randomization form which must be approved by the study investigator. On this form, information needed to stratify the patient must be identified and completed prior to randomizing the patient.

Eligible study participants will be randomized at the clinical site at the baseline visit, and will be assigned a study randomization number to which a treatment group assignment has been made. The IDS Research Pharmacist will provide the randomization number and treatment assignment. Subject identification numbers (SIN) will be randomly pre-assigned to study participants and the corresponding treatment group will be stored and assigned by the research pharmacist at investigational drug services based on treatment allocation. For each subject, the SIN, treatment and participant’s name will be entered into the study log.

5.3. Intensive Diabetes Management

During the study period, all participants will receive “intensive” management of their diabetes. The goal of the treatment will be to keep the HbA1c levels within the currently recommended American Diabetes Association target range in the absence of level 3 hypoglycemia or diabetic ketoacidosis. The primary responsibility for diabetes management will be the treating or referring diabetes care provider, but the research study team will provide close additional support through regular interaction. Subjects will not be permitted to use non-insulin pharmaceuticals for glycemic control.

Glucose levels should be checked frequently using either a continuous glucose monitor (CGM) or
manually via study participant’s glucometer. In addition, subject will complete a 7-day Blood Sugar record and Hypoglycemia log prior to each study visit starting at visit 1. Data obtained from participant’s glucometer, CGM, and blood sugar log will serve as source documentation of glucose values, insulin use, and records of the glucose levels communicated regularly to the study team. Records of communication with the participant will provide source documentation of this interaction. The study team will be evaluating the HbA1c data and provide additional guidance to the participants as needed to bring diabetes control within goals. Any episodes of level 3 hypoglycemia will prompt review by the study physician and site medical monitor with recommendations if any for changes in diabetes management conveyed to the participants in conjunction with the principal investigator(s).

5.4. Administration of Study Drugs

5.4.1. Omega-3 Fatty Acids

Omega-3 fatty acids (omega-3s) are a group of polyunsaturated fatty acids that are important for a number of functions in the body. Some types of omega-3s are found in foods such as fatty fish and shellfish. Another type is found in some vegetable oils. Omega-3s are also available as dietary supplements. This fact sheet provides basic information about omega-3s—with a focus on dietary supplements, summarizes scientific research on effectiveness and safety, and suggests sources for additional information.

Administration of high-dose omega 3 fatty acids (18g of marine lipid concentrate) for 6 weeks to healthy volunteers reduced the AA/EPA ratio from 20.9±2.2 to 2.4±0.2 (nearly 90%) and resulted in a decrease in IL-1β, IL-1α, and TNF and was well tolerated [1]. A recent study in patients with stable coronary artery disease showed that long-term treatment (1 year) with high-dose omega 3 fatty acids (3360 mg EPA and DHA daily) was associated with an increase in specialized pro-resolving lipid mediators and enhancement of macrophage phagocytosis of blood clots [2]. These data suggest that high-doses of omega 3 fatty acids are required to mitigate cytokine responses and may be critical to generate resolvins and protectins, which have been postulated as the molecular basis for the anti-inflammatory properties of omega-3 fatty acids.

Further, high-doses of omega 3 have been associated with improved clinical outcomes. In children with ADHD, a study evaluating an 8-week treatment course with high-dose omega 3 fatty acids (250-325 mg EPA and DHA/Kg/day) aimed at achieving an AA/EPA ratio between 1.5 and 3.0 resulted in significant improvements in behavior with the AA/EPA ratio correlating with the global severity of illness scores [3, 4]. In addition, two separate case reports in children with new onset type 1 diabetes have documented treatment with high-dose of omega 3 fatty acids (55-110 mg EPA and DHA/Kg/day) for over 1 year and showed improvement in glycemic control and preservation of C-peptide [5, 6]. Notably, these high doses of omega 3 fatty acids were well tolerated.

To appropriately gauge the dose of omega 3 fatty acids we are proposing the use of the AA/EPA ratio to guide dosing. As noted above, AA/EPA ratios in the 1.5 to 3.0 range have been studied in healthy
volunteers and in children with ADHD have shown an association with clinical outcomes and noted to be safe. Further, such low ratios can be achieved by diet alone as documented in the Japanese population where the average fish consumption has been reported to be one serving of 85 g (3 oz; 900 mg EPA and DHA) per day and 90% of individuals eat fish at least once a week [7].

In view of the chronic nature of the immunopathogenesis of type 1 diabetes it is then not unexpected that therapeutic interventions started at disease onset to preserve beta cell function have usually been administered for a duration of 6 month to 2 years [8-10]. It is important, however, to highlight that one of the main factors responsible for determining the duration of therapy is the safety profile of the proposed intervention.

Data from TrialNet intervention trials has allowed to study the decline in C-peptide 2 years following type 1 diabetes onset which shows a biphasic profile with a steeper decline during the first year [11] suggesting that processes involved with beta-cell loss may be more aggressive during the first year of diagnosis. Thus, therapies aimed to preserve beta-cell function in new onset disease may likely need to be administered over a prolonged period of time and for at least 1 year following disease onset.

In established disease, duration of therapy is also dependent on the mechanism of the intervention and the safety profile. Since inflammation affecting glycemic control may be a chronic state in patients with type 1 diabetes and in view of the reportedly safety profile of high-dose omega 3 fatty acids, we have proposed treating patients with established type 1 diabetes for a duration of 1 year.

5.4.1.1. **Ultra-refined omega-3 EPA/DHA concentrate (ZoneLabs® OmegaRx®2 Fish Oil) Administration**

Participants will receive ultra-refined omega-3 EPA/DHA concentrate (ZoneLabs® OmegaRx®2 Fish Oil – Liquid; containing 3375 mg EPA+DHA [2250 mg EPA and 1125 mg DHA] in 5 mL).

Research subjects will be started at a dose of 150 mg of EPA+DHA per Kg body weight. For example:

- The dose for a 22.5 Kg child will be:
  
  150 mg x 22.5 Kg = 3375 mg of EPA+DHA fish oil corresponding to 5 mL of Omega Rx ®2 Fish Oil Liquid.

- The dose for a 30 Kg child will be:

  150 mg x 30 Kg = 4500 mg of EPA+DHA fish oil corresponding to 6.7 mL of Omega Rx ®2 Fish Oil Liquid.

Participants who are unable to tolerate the liquid formulation will be switched to the OmegaRx®2 capsule formulation (containing 750 mg EPA+DHA [500 mg EPA and 250 mg DHA] in 1 capsule) at the same dose as described above.

It is 150 mg of combined EPA and DHA per kg body weight to be given either as a single or divided into smaller doses through the day.
5.4.1.2. Modification or Discontinuation of omega-3 EPA/DHA concentrate

Dose will be adjusted to maintain a target AA/EPA ratio of 1.5-3.0 as follows:
- If AA/EPA ratio is ≥ 7, double the dose and recheck ratio in one month
- If AA/EPA ratio is 4-6, increase dose by 50% and recheck ratio in one month
- If AA/EPA ratio is at target, maintain dose as prescribed
- If AA/EPA ratio is <1.5, reduce dose by 50% and recheck in one month

AA/EPA ratios will be monitored monthly until achieving target levels and as clinically indicated thereafter.

5.4.1.3. Discontinuation of omega-3 EPA/DHA concentrate

Subjects would be continuously evaluated for any untoward effects of Omega-3 fatty acid supplements or negative side effects. Typically side effects consist of minor gastrointestinal symptoms, such as belching, indigestion, or diarrhea, stomach pain or discomfort, burping, heartburn, vomiting, constipation, nausea, and change in the sense of taste. Joint pain may be a side effect as well.

Patients with coagulation, bleeding, or blood disorders will be excluded. We will monitor clotting times of enrolled subjects by measuring the prothrombin time (PT/PT-INR) during all subject visits, in addition to CBC with differentials (see schedule of assessment).

Symptomatic management of the side effects will be evaluated by the study physician and should the investigator believes that the study treatment is no longer in the best interest of the participant, subjects would be discontinued from the treatment. Similarly, if subject begins taking medications that affect clotting chronically, subjects would be discontinued and appropriately noted in the study record. Participants who prematurely discontinue study treatment will remain in the study and undergo all efficacy and safety assessments.

5.4.2. Vitamin D

Vitamin D is a nutrient found in some foods that is needed for health and to maintain strong bones. It does so by helping the body absorb calcium (one of bone's main building blocks) from food and supplements. People who get too little vitamin D may develop soft, thin, and brittle bones, a condition known as rickets in children and osteomalacia in adults.

Vitamin D is important to the body in many other ways as well. Muscles need it to move, for example, nerves need it to carry messages between the brain and every body part, and the immune system needs vitamin D to fight off invading bacteria and viruses. Together with calcium, vitamin D also helps protect older adults from osteoporosis. Vitamin D is found in cells throughout the body.

5.4.2.1. Vitamin D Administration

Vitamin D supplementation
1. For levels of Vitamin D 25OH of 30 -39 ng/ml:
   a. age ≤10 years give 500 IU daily
b. age >10 years give 1000 IU daily

2. For levels of Vitamin D 25OH of 20 – 29 ng/ml give 50,000 IU weekly for 2 months and then:
   a. age ≤10 years give 1000 IU daily
   b. age >10 years give 2000 IU daily

3. For levels of Vitamin D 25OH of < 20 ng/ml give 50,000 IU weekly for 4 months and then:
   a. age ≤10 years give 1000 IU daily
   b. age >10 years 2000 IU daily

Repeat vitamin D 25OH levels 1 week after the last 50,000 IU dose:
- For children whose levels are not above 30 ng/ml on repeat testing, repeat treatment as above.
- For children whose levels are 30 -39 ng/ml on repeat testing:
  o if age ≤10 years increase vitamin D supplementation to 1000 IU daily
  o if age is >10 years give 2000 IU daily

Thereafter, monitor vitamin D 25OH levels every 4 months (or more frequently at the discretion of the investigator) and adjust Vitamin D treatment to maintain levels > 40 ng/ml.

The Dietary Reference Intake Committee to Review Dietary Reference Intakes for Vitamin D and Calcium from Institutie of Medicine, recommends following upper intake levels for Vitamin D (see page 403-477) [https://www.ncbi.nlm.nih.gov/books/NBK56070/pdf/Bookshelf_NBK56070.pdf]

| Table Representing Tolerable Upper Intake Levels (ULs) for Vitamin D |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age             | Male            | Female          | Pregnancy       | Lactation       |
| 0–6 months      | 1,000 IU        | 1,000 IU        | 1,000 IU        | 1,000 IU        |
|                 | (25 mcg)        | (25 mcg)        | (25 mcg)        | (25 mcg)        |
| 7–12 months     | 1,500 IU        | 1,500 IU        | 1,500 IU        | 1,500 IU        |
|                 | (38 mcg)        | (38 mcg)        | (38 mcg)        | (38 mcg)        |
| 1–3 years       | 2,500 IU        | 2,500 IU        | 2,500 IU        | 2,500 IU        |
|                 | (63 mcg)        | (63 mcg)        | (63 mcg)        | (63 mcg)        |
| 4–8 years       | 3,000 IU        | 3,000 IU        | 3,000 IU        | 3,000 IU        |
|                 | (75 mcg)        | (75 mcg)        | (75 mcg)        | (75 mcg)        |
| ≥9 years        | 4,000 IU        | 4,000 IU        | 4,000 IU        | 4,000 IU        |
|                 | (100 mcg)       | (100 mcg)       | (100 mcg)       | (100 mcg)       |

Microcrystalline cellulose is the only excipient in Biotech Pharmacal Vitamin D3 capsule with following quantities:
- D3-5000 IU capsule contains 89 mg of microcrystalline cellulose
- D3-1000 IU capsule contains 92.8 mg of microcrystalline cellulose
- D3 50,000 IU capsule contains 115 mg of microcrystalline cellulose
Type of microcrystalline cellulose is Vivapur Type 101, it is pure microcrystalline cellulose that meets the requirements for Ph. Eur, NF, and JP monographs for Microcrystalline Cellulose and it complies with E460 (i) monograph and FCC as well.

5.4.2.2. Modification or Discontinuation of Vitamin D

Vitamin D is likely safe when taken by mouth in recommended amounts. Most people do not commonly experience side effects with vitamin D, unless too much is taken. Some side effects of excess vitamin D include weakness, fatigue, sleepiness, headache, loss of appetite, dry mouth, metallic taste, nausea, and vomiting.

Taking vitamin D for long periods of time in doses higher than 4000 units daily is possibly unsafe and may cause excessively high levels of calcium in the blood. However, much higher doses are often needed for the short-term treatment of vitamin D deficiency.

Vitamin D in very high doses can make the intestines absorb too much calcium which can cause high levels of calcium in the blood (hypercalcemia). This can cause side effects including nausea, vomiting, constipation, poor appetite, weakness, weight loss, confusion and disorientation. Hypercalcemia can also lead to kidney stones, damage to the kidneys, and cause calcium deposits in heart and lungs. We will monitor blood levels of vitamin D to minimize the risk of these side-effects.

5.4.2.3. Contraindications for Vitamin D Supplement

There are conditions where Vitamin D treatment require special precautions and these subjects will not be included in this study:

**Kidney disease:** Vitamin D may increase calcium levels and increase the risk of arteriosclerosis in people with serious kidney disease. This must be balanced with the need to prevent renal osteodystrophy, a bone disease that occurs when the kidneys fail to maintain the proper levels of calcium and phosphorus in the blood.

**Sarcoidosis:** Vitamin D may increase calcium levels in people with sarcoidosis. This could lead to kidney stones and other problems..

**Histoplasmosis:** Vitamin D may increase calcium levels in people with histoplasmosis. This could lead to kidney stones and other problems..

**Over-active parathyroid gland (hyperparathyroidism):** Vitamin D may increase calcium levels in people with hyperparathyroidism..

**Lymphoma:** Vitamin D may increase calcium levels in people with lymphoma. This could lead to kidney stones and other problems..

**Tuberculosis:** Vitamin D might increase calcium levels in people with tuberculosis. This might result in complications such as kidney stones.

5.4.3. Assessment of Participant Compliance with Study Agent
Patients will be closely monitored to assess compliance of study drug administration. Each participant will keep a log and will return the empty bottles to the Coordinator to assess compliance, which in turn will be returned to the Pharmacy for appropriate on-site destruction and for documentation purposes.

5.4.4. Prior and Concomitant Treatments

The use of concomitant medications will be assessed at each study visit and recorded on an appropriate source document and CRF. Participants are allowed to use preparations of insulin as advised by the investigator or the referring physician.

The following medications are prohibited during participation in this study:

- Agents that influence insulin sensitivity or secretion (e.g. pramlintide, sulfonylureas, metformin, diphenylhydantoin, thiazide, or other potassium-depleting diuretics, beta-adrenergic blockers, niacin etc).

If participants receive, or if the investigator believes that participants must receive, any of the above medications, the case must be immediately discussed with the medical monitor. The use of prohibited medications must be documented on the source document and CRF, and a protocol deviation must be requested. A decision regarding continuation of the participant in the trial will be made by the study PI, and the medical monitor.

5.4.5. Removal of Subjects from Therapy or Subject Withdrawal or Early Termination

- **Withdrawal of consent** - Participants who withdraw consent will be asked to complete all the assessments listed for the end of treatment follow-up
- **Failure to return** - Participants who do not return for visits and who do not respond to repeated attempts by the site staff to have them return will be considered lost to follow-up.
- **Investigator judgment** - A severe or serious AE occurs, which, based on the medical judgment of the investigator, prevents completion of participation in the study.

5.4.6. Discontinuation of study drug(s) in an individual patient

The dosing and administration of investigational medication according to study specification will be discontinued for an individual participant if any of the following criteria is met:

- Subjects who have 3 severe hypoglycemic reactions on separate days (requiring assistance from another individual)
- Subjects who have nausea or vomiting that precludes adherence to diet will discontinue the use of the study drug.
- Subjects who lose more than 10 kg in weight from baseline.
• Any grade 3 or higher AE occurs that, based on the medical judgment of the investigator, the medical monitor, and the clinical trial physician, prevents completion of the course of infusions.

• Any unexpected, treatment-related SAE resulting in permanent treatment discontinuation and not related to glycemic events.

• The investigator determines that it is in the participant’s best interest to discontinue treatment.

• The participant, or participant’s legal representative, requests that treatment be halted.

• The participant becomes pregnant.

Further care will be provided according to the judgment and practice of the investigator. The participant will be asked to remain in the study and participate in follow-up. If study treatment is discontinued, the medical monitor will be notified. Participants who prematurely terminate from the study will not be replaced.

5.4.7. Re-Entry into Study Treatment

In some circumstances, a participant may temporarily discontinue the study medication and/or not return to the study clinic for follow-up visits. If the participant decides to return for study treatment and/or follow-up assessments at a later date, he or she will be allowed and encouraged to do so.

The study will be conducted according to the intent-to-treat principle. This means that once randomized into the study, a participant will be expected to undergo all scheduled follow-up assessments and will remain in the assigned treatment group for purposes of statistical analysis regardless of the actual course of treatment administered. Withdrawal from treatment does not automatically entail withdrawal from the study. Withdrawal from the study will only occur if the participant dies or withdraws consent. Subjects who withdraw consent are classified as inactive but may again become active upon re-entry into the study, if they so choose.

5.4.8. Risk to the Subjects

The risks of these over the counter drugs is summarize below:

• Omega-3 Fatty Acids may cause gastrointestinal side-effects including stomach pain or discomfort, burping, heartburn, vomiting, constipation, diarrhea, nausea, and change in the sense of taste. Joint pain may be a side effect as well.

• Vitamin D in very high doses can make the intestines absorb too much calcium which can cause high levels of calcium in the blood (hypercalcemia). This can cause side effects including nausea, vomiting, constipation, poor appetite, weakness, weight loss, confusion and disorientation. Hypercalcemia can also lead to kidney stones, damage to the kidneys, and cause calcium deposits in heart and lungs. We will monitor blood levels to minimize these risks.
*Allergic reaction:* As with any drug, it is possible that subjects could experience an allergic reaction to OMEGA-3, or Vitamin D. Such allergic reactions include: itching, skin rash, sudden drop in blood pressure, loss of consciousness and/or associated with seizures, including the possibility of death.

*Blood draw risks:* Drawing blood may cause temporary pain from the needle stick, bruising or swelling at the site, and rarely, infection or fainting.

*Hypoglycemia:* These medications could lower blood sugar too much (hypoglycemia). This could make subjects feel tired, dizzy, sweaty, and/or nauseated. Also, it could cause heart to feel as if it is racing. There may also be other effects. Untreated hypoglycemia could cause convulsions, loss of consciousness, and can lead to death. The clinical research team will provide added training and education to subjects to better manage hypoglycemia and other diabetes related complications.

*Unknown Risks:* The experimental drug may have side effects that no one knows about yet. The researchers will let you know if they learn anything that might make you change your mind about participating in the study.

Females of child bearing potential must have a negative pregnancy test prior to enrolling in the study and will be required to use at least two FDA approved birth control during the study. At every study visit the sexual activity of female participants of reproductive age will be re-assessed. Pregnancy testing will be conducted in females in reproductive age at 4, 8, 12 and 16 months study visit. If a subject who was previously sexually inactive becomes sexually active, she will be counseled about the need to use a reliable forms of birth control. Subjects will be requested to avoid pregnancy for 6 months following the last study administration and instructed to use birth control. If subject becomes pregnant, study intervention will be discontinued and subject withdrawn from study.

6. **STUDY ASSESSMENTS**

6.1. **General Assessments**

After screening to determine eligibility, study visits will be monitored closely and first dose of the medications (Omega-3 Fatty Acids plus Vitamin D in Arm A or Vitamin D alone in Arm B) will be given at site. Patients visits will occur for all subjects at baseline (day 0), and every four months thereafter (month 4, 8, and 12) and consist of treatment adherence and outcome assessments. Subjects will be provided with supply of study drugs to take home and administer orally. Subjects will be educated and trained for the drug administration and study personnel will evaluate drug returns and treatment adherence. Subjects will be advised to bring the used medication back to site during their next visit. At the end of one year, all subjects will continue with assessments up to an additional one year (months 16, 20, and 24).

The time each assessment will be performed relative to dosing is shown in the Schedule of Study Activities (Appendix 1).

General assessments include:
• Medical history: To determine if there are any clinically significant diseases or medical procedures other than the disease under study.
• Physical examination: Includes any body system with clinical signs or reported symptoms of adverse events and weight loss.
• Concomitant medications
• Adverse events

6.2. Enrollment
The research study will be explained in lay terms to each potential research participant. The potential participants will sign an informed consent before undergoing any study procedures. The consent form will be reviewed with participants and the participants will be given time to review the written consent form and ask questions. The participant will be given a copy of their signed consent form. For the purpose of this protocol, once the patient has signed informed consent, he/she will be assigned a unique number, will be randomized and will receive the first dose of treatment.

6.3. Screening (visit -1) and Baseline visits
Subjects will be evaluated based on the diagnosis of T1D duration - for new onset subjects, screening visit will occur when a patient has been diagnosed with T1D within the last 180 days. For established T1D, subjects should have T1D for more than 180 days. For this visit, the patient will be required to be fasting, with no fever, illness or consumption of excluded medications during the preceding 7 days.

Patients will be asked to sign consent for screening to determine eligibility. Patients will receive a physical exam, medical history will be taken, and basic physical parameters will be recorded (height, body weight, heart rate, blood pressure). Blood will be drawn to screen for evaluating inclusion and exclusion criteria, determine HbA1c and T1D associated autoantibodies (GAD, IA-2, ZnT8; insulin autoantibodies are induced by insulin injections and thus are not useful at this stage).

A patient that meets the entry criteria will be offered consent to enroll in the trial, and can then be formally enrolled and randomized to one of the two treatment arms. Blood will be drawn for baseline assessments. The patient will receive the first treatment dose at this visit.

6.4. Diabetes Management
During the study period, all participants will receive “intensive” management of their diabetes. The site has diabetes clinics that provides intensive diabetes management. The patients will continue to see their primary endocrinologist during the study period. All participants will be expected to take a sufficient number of daily insulin injections to meet the glycemic targets. In general, the expectation is that all participants will receive at least three injections of insulin daily, including short- and long-acting insulin preparations, or will utilize continuous subcutaneous insulin infusion (CSII insulin pump). All participants will be asked to adjust their prandial insulin dosages if the participant’s glycemic control changes during the study period.
Glucose levels should be checked either via continuous glucose monitor or manually at least 6 times daily via the study participant’s glucometer for 7 days prior to each visit starting at visit 1. Records of glucose measurements and communication with the participant will be kept as source documentation. Insulin use and hypoglycemia events will be recorded at each visit. Participants will be required to record the daily amount of insulin they have used during the 7-day period immediately preceding each study visit using the 7-day Blood Sugar record and Hypoglycemia log provided. Log books will be provided to participants at the start of the study and information regarding their insulin usage and glucose levels will be collected at each visit and will serve as source documents. Upon review of these records, the investigator may make adjustments in the insulin regimen, refer a participant to a registered dietician or if necessary take other approaches that will help to maintain or improve a participant’s glucose control.

Participants will also be contacted by the study coordinator or study nurse as necessary between visits to assess their diabetes. We will also ask the participants to record the date, time and dose of each drug taken in their log book. This information will be collected at each visit and serve as source documents.

### 6.5. Laboratory Assessments

The following laboratory assessments will be performed during the study:

- Chemistry (sodium, potassium, chloride, CO2, glucose, BUN, creatinine, TSH)
- Liver function tests (ALT, AST, alkaline phosphatase, total protein, albumin, total and direct bilirubin)
- Hematology (complete blood count with differential, platelets, Prothrombin time [PT/PT-INR])
- Urine pregnancy test as appropriate
- Autoantibodies (e.g. ICA, GAD65, ICA512, mIAA)
- Samples for thyroid antibodies, virology and other immunization titers

### 6.6. Mechanistic Outcome Assessments

The DRI will perform immune assays to further understand mechanisms that may be underlying the Type 1 disease process and response to therapy. For this purpose, samples will be obtained and stored for future analysis.

### 6.7. Metabolic Outcome Assessments

Metabolic assessments will consist of:

- Glucose records and reports of hypoglycemia: collected in subject’s continuous glucose monitor, glucometer, and 7-day blood sugar record and hypoglycemia log.
- Insulin dose
- HbA1c
- Clarke Score
- Mixed meal tolerance test (MMTT)

6.8. Visit Windows

The initial study drug administration must begin within 180 days from the day of diagnosis. All subsequent treatment visits and follow up visits in Appendix 1 must occur within the time limits specified below:

*The table below depicts summary of visit windows.*

<table>
<thead>
<tr>
<th>Visit</th>
<th>Visit Windows</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>At least 2 weeks before visit 1</td>
</tr>
<tr>
<td>1</td>
<td>New onset group (randomization ≤180 days T1D diagnosis) or established T1D (&gt;180 days T1D diagnosis) post diagnosis</td>
</tr>
<tr>
<td>2-4</td>
<td>± 25 days</td>
</tr>
<tr>
<td>Follow-up between year 1 and 2 Every four months</td>
<td>± 25 days</td>
</tr>
</tbody>
</table>

During the course of the study, participants who complete one year treatment will receive combination therapy of Omega-3 Fatty Acids and Vitamin D or Vitamin D alone. In addition, participants will frequently undergo assessments of their insulin production, immunological status, and overall health. The participant’s insulin production will be measured by a series of MMTTs conducted regularly during the study. The participant’s diabetes control will be evaluated by measuring HbA1c every four months and clinical records including insulin types, doses, administration times and blood glucose records.

6.9. Unscheduled visits

Patients will be instructed to contact the study coordinator for any health concern, side effects potentially associated with the study, or other concern that may affect their participation and require an unscheduled visit.

6.10. Sample retention

Biological specimens collected in this trial may be used to reevaluate biologic responses as new research tools become available. The specimens will be stored at the laboratory of the individual investigators at Diabetes Research Institute of University of Miami. Specimens for future mechanistic studies will be obtained throughout the study. Residual specimens may be used by the investigators for studies of immunologic mechanisms involved in T1D.
7. PARTICIPANT SAFETY

7.1. Staggering Administration

Please note that the enrollment of patients in this trial is staggered across individuals. Initially, as total of 6 subjects will be randomized in each of the following groups:

<table>
<thead>
<tr>
<th>Group</th>
<th>Subject population</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Fourteen (14) adults (18-65 years) of established T1D of more than 6 months duration (&gt;180 days) and up to 10 years</td>
</tr>
<tr>
<td>II</td>
<td>Fourteen (14) adults (18-65 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days)</td>
</tr>
<tr>
<td>III</td>
<td>Fourteen (14) children (6-17 years) of established T1D of more than 6 months duration (&gt;180 days) and up to 10 years</td>
</tr>
<tr>
<td>IV</td>
<td>Fourteen (14) children (6-17 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days)</td>
</tr>
</tbody>
</table>

All 24 subjects will be monitored for acute and subacute adverse events for 90 days and a formal DSMB (Data and Safety Monitoring Board) will review the data and safety prior to treating additional subjects. This will limit the number of subjects who might be exposed to any unanticipated safety risk.

7.2. Intensive T1D Management

Patients with T1D must administer multiple daily injections of insulin to control glucose metabolism. Dosing and schemes vary by patient. During the study period, all participants will receive “intensive” management of their diabetes. The goal of the treatment will be to keep the HbA1c levels within the currently recommended American Diabetes Association age-specific target range in the absence of significant or level 3 hypoglycemia or diabetic ketoacidosis. The primary responsibility for diabetes management will be the treating or referring diabetes care provider, but the research study team will provide close additional support through regular interaction. Subjects will not be permitted to use non-insulin pharmaceuticals for glycemic control. Glucose levels should be checked frequently and records of the glucose levels communicated regularly to the study team. Records of communication with the participant will provide source documentation of this interaction.

7.3. Safety Monitoring

The members of the Data Safety Monitoring Board (DSMB) are independent and serve in an individual capacity to provide their expertise and recommendations. They will review the 90 day data of the first 6 subjects, and then periodically review and evaluate the accumulated study data for participant safety, study conduct and progress, and, when appropriate, efficacy, and make recommendations to study investigators concerning the continuation, modification, or termination of the trial. The DSMB members will comprise of experts in the field of T1D immunotherapy and will consider study-specific data as well as relevant background knowledge about the disease, test agents, and patient population under study.
The DSMB is responsible for defining its own deliberative processes, including event triggers that would call for an unscheduled review, stopping guidelines, and voting procedures prior to initiating any data review.

7.4. **Ad-hoc DSMB Reviews**

In addition to the pre-scheduled data reviews and planned safety monitoring, the DSMB may be called upon for ad hoc reviews. The DSMB will review any event that potentially impacts safety at the request of the study investigator. In addition, the following events will trigger an *ad-hoc* comprehensive DSMB Safety Review:

- Any death that occurs in the study.
- The occurrence of a Grade 3 or higher related and unexpected SAE in three or more of the study participants who have received a study treatment.

After review of the data, the DSMB will make recommendations regarding study conduct and/or continuation.

7.5. **Temporary Suspension of Enrollment/Drug(s) Dosing or Both**

A temporary halt in enrollment will be implemented if an *ad-hoc* DSMB safety review is required. Subjects already on investigational product will continue on therapy unless the *ad-hoc* DSMB review is completed and the DSMB determines that its findings warrant cessation of study drug(s). Subjects in the screening phase of the study may continue to undergo screening procedures.

7.6. **Stopping rules**

As stated earlier, the progress of the study will be monitored by the DSMB which will review safety data and make recommendations regarding continuation, termination, or modification of the study. Based on a 12 month enrollment period and an additional study period of 12 months, the DSMB will formally review the safety data after participant number 24 reaches day 90 of the study. The number of subjects who discontinue study treatment will also be included in the reports prepared for the DSMB.

In addition, safety data will be reviewed by the DSMB when an event occurs that is of sufficient concern to the medical monitor and/or study investigator(s) to warrant review, or when an event occurs that contributes to a stopping rule listed below.

- **Patient stopping rules**: Subjects who have 3 severe hypoglycemic reactions (requiring assistance from another individual) on separate days or who have nausea or vomiting that precludes adherence to diet will discontinue the use of the study drug. Subjects who lose more than 10 kg will also discontinue study drug. Subjects who discontinue the drug treatment will not be replaced.
- **Trial stopping rules**: Interim analysis will be conducted when recommended by the DSMB to review safety data, including metabolic, immunological assessments and adverse events. The
DSMB may recommend early stopping if there is sufficient evidence to conclude that the investigational treatment is harmful based on interim analysis of safety endpoints.

7.7. Potential Benefits

The risks of this study in detailed are presented in the informed consent form. This study will examine whether combination supplement therapy intervention will preserve beta cell function, but there is no guarantee that this will occur.

This is a pilot feasibility trial with the prospect of direct benefit to the individual subjects for their participation in the study. The potential direct benefit to research subjects is that administration of specific combination supplement therapy or vitamin D alone could stabilize or improve β-cell function, thus facilitating attainment of improved glycemic control. All subjects will benefit from being closely involved with an experienced team of diabetes experts, with the likely benefit that their glycemic control will be better than would be otherwise obtained. Thus, these potential benefits include the recognized benefits of being in a clinical study, including close monitoring and additional resources available to maintain tight glycemic control offered to all subjects, regardless of group assignment. These additional resources include frequent in-person and other contact with study associate diabetes educator throughout the duration of the study. Further, the intervention has the prospect of direct benefit to a given subject and is likely to yield general knowledge about T1D which is of importance for the understanding and amelioration of T1D. The study procedures, while greater than minimal risk, offers the possibility of benefit due to the close monitoring for all participants.

If effective in preserving or increasing β-cell function, combination therapy could be an important new treatment to change the course of T1D, thus benefiting the individual research participant and potentially society at large. Moreover, the proposed studies will produce new information about the immune system and its regulation, in the context of T1D and in relation to therapy with these over the counter agents that would be relevant to other autoimmune diseases.

7.8. Pregnancy

Pregnant and lactating women will not be included in the study. Sexually active females must have a negative pregnancy test prior to enrolling in the study and will be required to use at least two FDA approved birth control during the study. At every study visit the sexual activity of female participants of reproductive age will be re-assessed. If a subject who was previously sexually inactive becomes sexually active, she will be counseled about the need to use a reliable forms of birth control. Subjects will be requested to avoid pregnancy for 6 months following the last study administration and instructed to use birth control.

7.9. Protecting Against or Minimizing Potential Treatment Risks

Subjects will not be enrolled who have other active serious medical problems. Frequent monitoring of patients with history, physical examination, and laboratory studies will allow for early identification of
adverse events. All participants will be required to have adequate hemoglobin to allow frequent
venipuncture. The supplement drugs will be dispensed to subjects free of cost, and subjects will be
closely monitored during and after the treatment.

Subjects will be counseled about the potential risk for gastrointestinal side effects and the need to report
any change in health status between or at the time of visits. Directed questioning about concurrent
illness will occur before each treatment.

7.10. Supplement - Drug Interaction

Vitamin D
Like most dietary supplements, vitamin D may interact or interfere with other medicines or
supplements. Here are several examples:

- Corticosteroid medicines to reduce inflammation impair how the body handles vitamin D, which
  leads to lower calcium absorption and loss of bone over time.
- Both the weight-loss drug orlistat (brand names Xenical® and Alli®) and the cholesterol-
  lowering drug cholestyramine (brand names Questran®, LoCholest®, and Prevalite®) can
  reduce the absorption of vitamin D and other fat-soluble vitamins (A, E, and K).
- Both phenobarbital and phenytoin (brand name Dilantin®), used to prevent and control epileptic
  seizures, increase the breakdown of vitamin D and reduce calcium absorption.

Omega-3 Fatty Acids
Omega-3 Fatty Acids can affecting medications that influence blood clotting phenomenon, some of
which includes:

- Antiplatelet Medication: Anagrelide (Agrylin®), aspirin(any brand, all doses), cilostazol
  (Pletal®), clopidogrel (Plavix®), dipyridamole (Persantine®), dipyridamole/aspirin
  (Aggrenox®), enteric-coated aspirin (Ecotrin®), ticlopidine (Ticlid®)
- Anticoagulant Medication: Anisindione (Miradon®), Arixtra, enoxaparin (Lovenox®) injection,
  Fragmin, heparin injection, Pradaxa, pentosan polysulfate (Elmiron®), warfarin (Coumadin®),
  Xerelto
- Nonsteroidal Anti-Inflammatory Drugs: Celebrex, diclofenac (Voltaren®, Cataflam®), diflunisal
  (Dolobid®), etodolac (Lodine®), fenoprofen (Nalfon®), flurbiprofen (Ansaid®), ibuprofen
  (Motrin®, Advil®, Nuprin®, Rufen®), indomethacin (Indocin®), ketoprofen (Orudis®, Actron®),
  ketorolac (Toradol®), meclofenamate (Meclomen®), meloxicam (Mobic®), nabumeton
  (Relafen®), naproxen (Naprosyn®, Naprelan®, Aleve®), oxaprozin (Daypro®), piroxicam
  (Feldene®, salsalate (Salflex®, Disalcid®), sulindac (Clinoril®), sulfinpyrazone tolmetin
  (Tolectin®), trilisate (salicylate combination)
- Herbs/Vitamins: Ajoene birch bark, cayenne, Chinese black tree fungus, cumin, evening primrose oil, feverfew, garlic, ginger, ginkgo biloba, ginseng, grape seed extract, milk thistle, onion extract, St. John’s wort, turmeric, vitamins C and E.

The study team will evaluate the list of all medications and its interaction with Vitamin D or Omega-3 Fatty Acids dietary supplements patients take. Study team will educate and may alter medical treatment if dietary supplements might interact or interfere with their prescription or over-the-counter medicines, or if the medicines might interfere with how patients body absorbs, uses, or breaks down nutrients.

8. ADVERSE EVENT REPORTING AND SAFETY MONITORING

8.1. Adverse Event Definition

8.1.1. Adverse Event (AE)

In this clinical study, an adverse event is any occurrence or worsening of an undesirable or unintended sign, symptom or disease whether or not associated with the treatment and study procedures.

Throughout the study, the investigator must record all adverse events on source documents. Events not related to hypo or hyperglycemia that are Grade 2 or greater per the NCI CTCAE (see Grading Event Severity below) will be reviewed by study physician and medical monitor on the appropriate adverse event form. The investigator will treat participants with adverse events appropriately and observe them at suitable intervals until the events resolve or stabilize.

Adverse events may be discovered through:

- observation of the participant;
- questioning the participant;
- unsolicited complaint by the participant

In questioning the participant the questioning should be conducted in an objective manner.

8.1.1.1. Disease specific AE

For the purposes of this study, hypoglycemia events will be recorded as follows:

- Level 1: glucose < 70 mg/dl (3.9 mmol/l) and glucose ≥ 54 mg/dl (3.0 mmol/l).
- Level 2: glucose < 54 mg/dl (3.0 mmol/l)
- Level 3: a severe event characterized by altered mental and/or physical status requiring assistance.

Level 2 and Level 3 hypoglycemic events must be reported as adverse events on the case report forms. All episodes of Level 3 hypoglycemia will be reported as SAEs to the DSMB.
Hypoglycemia grading according to CTCAE version 4.0

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoglycemia</td>
<td>&lt;LLN-54 mg/dL</td>
<td>&lt;54-40 mg/dL</td>
<td>&lt;40-30 mg/dL</td>
<td>&lt;30 mg/dL; life threatening consequences; seizures</td>
<td>Death</td>
</tr>
</tbody>
</table>

All reported hypoglycemic episodes accruing during the treatment period or within 4 weeks of treatment end will be defined as possibly related to study treatment.

Hyperglycemia will not be collected as an adverse event, unless it results in an inpatient hospitalization.

### 8.1.2. Serious Adverse Event

For this trial, an adverse event associated with the treatment or study procedure that suggests a significant hazard, contraindication, side effect or precaution (as described below) is to be reported as a serious adverse event (SAE). A serious adverse event (experience) or reaction is any untoward medical occurrence that:

- results in death,
- is life-threatening,
- requires inpatient hospitalization or prolongation of existing hospitalization,
- results in persistent or significant disability/incapacity, or
- is a congenital anomaly/birth defect.

Important medical events that may not result in death, be life threatening, or require hospitalization may be considered serious adverse events when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed above.

### 8.1.3. Unexpected Adverse Event

An adverse event is considered unexpected when the nature (specificity) or severity of the event is not consistent with the risks described in the protocol or informed consent document for a particular protocol.

### 8.1.4. Grading Event Severity

This study will adopt the National Cancer Institute (NCI) Common Technology Criteria for Adverse Events (CTCAE) and/or study-specific criteria for classification to describe the severity of adverse events with the exception of hyper and hypoglycemia. For this study, a reportable hypoglycemic event is defined as Level 3 (a severe event characterized by altered mental and/or physical status requiring assistance) and hyperglycemic event is one resulting in Diabetes Keto Acidosis (DKA).
8.1.5. Evaluation of Adverse events

A non-serious adverse event is an AE not classified as serious. Both serious and non-serious AEs should be graded with respect to severity on the following 3 point scale and reported, in detail, on the appropriate CRF page:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Discomfort noticed, but no disruption of normal daily activities; event usually requires no intervention.</td>
</tr>
<tr>
<td>Moderate</td>
<td>Discomfort sufficient to reduce or affect normal daily activities; even may require intervention.</td>
</tr>
<tr>
<td>Severe</td>
<td>Incapacitating, with inability to perform normal daily activities; event usually requires treatment or other intervention. Subject may not be able to continue in the study.</td>
</tr>
</tbody>
</table>

The Investigator should evaluate the relationship of each AE to the study treatment regimen, using the following criteria:

<table>
<thead>
<tr>
<th>Relationship</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrelated</td>
<td>Another cause of the AE is more plausible; a clinically plausible temporal sequence is inconsistent with the onset of the AE and administration of the study treatment regimen; or a causal relationship is considered biologically impossible.</td>
</tr>
<tr>
<td>Possibly related</td>
<td>There is a clinically plausible time sequence between onset of the AE and administration of the study treatment regimen, but the AE could also be attributed to concurrent or underlying disease, or the use of other drugs or procedures. “Possibly Related” should be used when the study treatment regimen is one of several biologically plausible AE causes.</td>
</tr>
<tr>
<td>Definitely Related</td>
<td>The AE is clearly related to use of the study treatment regimen.</td>
</tr>
</tbody>
</table>

8.1.6. Adverse Event Reporting and Monitoring

Study personnel will assess adverse events and the use of concomitant medications throughout the study. They will be graded as to severity according to common toxicity criteria or study-specific criteria and the investigator will make a determination as to the relation to therapy. Events will be assessed and reported in accordance with the ICH Guideline for Good Clinical Practice and per the guidance of the DHHS Office for Human Research Protections (OHRP). The adverse event case report for the protocol must be documented for all adverse events (AE) of Grade 2 or greater severity regardless of relationship to therapy. For reporting serious adverse events (SAE), the MedWatch Form should also be completed and sent to medical monitor within 24 hours of when the site was notified of the event. This will be reviewed by the study physicians and Medical Monitor, and the Data and Safety Monitoring Board (DSMB) as appropriate. Deaths must be reported immediately. Event outcome and other follow-up information regarding the treatment and resolution of the event will be obtained and reported when
available, if not known at the time the event is reported. The follow-up information should contain sufficient detail to allow for a complete medical assessment of the case and an independent determination of possible causality.

Adverse events will be assessed by the Medical Monitor. The DSMB will conduct regular safety reviews approximately every three to six months (and, as needed) of adverse events by treatment group assignment. Serious adverse events as well as adverse events leading to treatment discontinuation will be reviewed by the DSMB.

Fatal or life-threatening events thought to be caused by study drug(s) should be reported to the Medical Monitor, or CRA immediately, as follows:

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Telephone Number</th>
<th>Pager Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Monitor</td>
<td>George W. Burke, III M.D., FACS Professor of Surgery</td>
<td>(305) 355-5111</td>
<td>(305) 355-5134</td>
</tr>
<tr>
<td>Director, Division of Kidney and Pancreas Transplantation, 1801 NW 9th Floor, Miami, FL 33136</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:GBurke@med.miami.edu">GBurke@med.miami.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical Research Operations &amp; Regulatory Support (CRORS), Miller Office of Research, University of Miami, Miller School of Medicine, Dominion Towers 4th floor, 1400 N.W. 10th Avenue; Suite 401, Miami, FL 33136</td>
<td>(305) 243-0133</td>
<td>(305) 243-5392</td>
</tr>
</tbody>
</table>

8.1.7. Recording Adverse Events

To improve the quality and precision of AE data, Investigators should observe the following guidelines:

- Whenever possible, use recognized medical terms when recording AEs on the AE page of the CRF. Do not use colloquialisms, jargon, or abbreviations.

- If known, record the diagnosis (ie, disease or syndrome) rather than component signs and symptoms on ae pages of the CRF (eg, record “congestive heart failure” rather than “dyspnea”, “rales”, and “cyanosis”). However, signs and symptoms that are considered unrelated to an encountered syndrome or disease should be recorded as individual AEs on the CRF page. For example, if congestive heart failure and severe headache are observed at the same time, each event should be recorded as an individual AE.

- Adverse events occurring secondary to other events (ie, sequelae) should be identified by the primary cause. A primary ae, if clearly identifiable, generally represents the most accurate clinical term to record on ae pages of the CRF. If a primary SAE is recorded on an AE CRF
page, events occurring secondary to the primary event should be described in the narrative description of the event.

- Laboratory abnormalities that are defined as clinically significant are to be considered AEs and recorded on the AE CRF page.

8.1.8. Adverse Events Requiring Expedited Reporting

Serious AEs require expedited reporting to the Sponsor or designee, regardless of the relationship of the event to the study treatment regimen. Refer to the previous section for the definition of a serious adverse event.

Investigators should report all SAEs to the Sponsor or designee within 24 hours of the observation or learning of the event. For initial SAE reports, the Investigator should record all case details that can be garnered on the SAE form and the AE CRF page.

The completed SAE form and Cover Sheet should be faxed within 24 hours to the medical monitor at (305) 355-5134 or via email GBurke@med.miami.edu. Relevant follow-up information is to be submitted to the Sponsor or its designee as soon as it becomes available.

8.1.9. Special Reporting Situations

Death: Death is an outcome of an event. The event that resulted in death should be recorded and reported on the SAE form and the AE CRF page.

Hospitalization for Surgical or Diagnostic Procedures: The illness leading to the surgical or diagnostic procedure is to be recorded as the SAE, not the procedure itself. The procedure is to be captured in the case narrative as part of the action taken in response to the illness.

8.1.10. Laboratory Test Result Abnormalities

The following laboratory test result abnormalities should be captured on the non-serious AE CRF page or SAE Report Form (paper or electronic) as appropriate:

- Any laboratory test result that is clinically significant or meets the definition of an SAE
- Any laboratory test result abnormality that required the subject to have study drug discontinued or interrupted
- Any laboratory test result abnormality that required the subject to receive specific corrective therapy.

It is expected that wherever possible, the clinical rather than laboratory term would be used by the reporting investigator (e.g. anemia versus low hemoglobin value).

8.1.11. Pregnancy

If, following initiation of the study product(s), it is subsequently discovered that a study subject is pregnant or may have been pregnant at the time of investigational product exposure, including up to
12 weeks after last product administration, the study product(s) will be permanently discontinued in an appropriate manner (e.g. dose tapering if necessary for subject safety).

They must be reported to the medical monitor within 24 hours by fax to (305) 355-5134 with a confirmatory telephone call to (305) 355-5111 and in accordance with SAE reporting procedures described above.

Any pregnancy that occurs in a female partner of a male study participant should be reported to the medical monitor.

8.1.12. Overdose

All occurrences of overdose must be reported as SAEs (see SAE reporting section for details).

An overdose is defined as the accidental or intentional administration of any dose of a product that is considered both excessive and medically important. All occurrences of overdose must be reported as an SAE.

8.1.13. Other Safety Considerations

Any significant worsening noted during interim or final physical examinations, electrocardiogram, x-ray filming, any other potential safety assessment required or not required by protocol should also be recorded as a non-serious or serious AE, as appropriate, and reported accordingly.

9. DATA QUALITY ASSURANCE

Accurate, consistent, and reliable data will be ensured through the use of standard practices and procedures. These are described in the following sections.

9.1. Data Collection, Monitoring, and Transfer

Adverse events will be collected from the initiation of study drug and be followed to resolution or until 30 days after the participant completes participation, whichever comes first.

Adverse events may be collected as follows:

- Observing the participant.
- Questioning the participant in an objective manner.
- Receiving an unsolicited complaint from the participant.

An abnormal value or result from a clinical or laboratory can also indicate an adverse event. If this is the case, then the evaluation that produced the value or result should be repeated until the value or result returns to normal or can be explained and the participant’s safety is not at risk. If an abnormal value or result is determined by the investigator to be clinically significant, it must be indicated as such.
on the appropriate laboratory evaluation form(s), and must also be reported as an adverse event on
the adverse event form. Abnormal vital sign measurements or laboratory finding deemed not clinically
significant by the site investigator must be documented as such and are not required to be listed in the
adverse event source documents or adverse event case report form. The DRI will perform data
collection, monitoring, and transfer tasks. A Clinical Research Monitor designated by Sponsor will be
responsible for monitoring the clinical study in accordance with current federal and relevant foreign
regulations. The Monitor will periodically collect the CRFs and brought them to Sponsor. Data on CRFs
will be double-entered into the database system and verified.

9.2. Quality Control and Quality Assurance
The Sponsor will perform a clinical review to define the level of resolution required of each data field,
with major safety fields (eg, AE) given the highest importance.
The database will be 100% verified against the CRFs. A clinical review will be performed at DRI to
identify those minor issues that could remain unresolved.

10. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

10.1. Overview
This study will test the hypothesis that combination therapy, administered for one year to patients with
established T1D and residual stimulated C-peptide secretion, will retain C-peptide secretion and
increase Treg proportions and function, in turn inhibiting ongoing islet autoimmune responses at one
year post treatment. Thus, the primary objectives of this study are to assess, at 1 year post
randomization, the efficacy of combination therapy, specifically whether combination therapy preserves
C-peptide secretion and improves proportions of Treg cells, compared to placebo, in patients with
established T1D.

10.2. Endpoints/Outcomes
The study includes primary endpoints, assessed at 1 year as:

Primary endpoint:

- Stimulated (90 minute sample of a MMTT) C-peptide at the 1 year visit greater or equal to
  baseline level.

Secondary Objective(s)

- Stimulated C-peptide area under the curve during a 4-hour MMTT greater or equal to baseline
  level, at the 1 year visit.
- Reduction in HbA1c at the one year visit compared to baseline.
- Reduction in insulin requirement at the 1 year visit compared to baseline.
- Incidence of adverse events (AE) comparable to general diabetes population.
10.3. **Measures to Minimize Bias**
After participants sign the consent form, they will be randomized to the 2 arms. The randomization will be performed by the University of Miami Research Pharmacy. The participants will be informed regarding the intervention assignment. The investigator and clinic personnel will also know the study assignment.

10.4. **Analysis Plan**
The details of the analyses will be provided in the statistical analysis plan (SAP) below.

10.4.1. **Analysis Populations**
Analyses of study data will be conducted to address all objectives of the trial and other interrelationships among data elements of interest to the investigators and of relevance to the objectives of the study. Primary analysis of treatment effect will be conducted under the intention-to-treat principle of eligible patients whereby outcome data from all eligible patients will be included regardless of treatment compliance.

10.4.2. **Primary Analysis of Primary Endpoint(s)/Outcome(s)**
The metabolic primary outcome is the 90-minute stimulated C-peptide following MMTT, conducted at the 1 year visit. The primary statistical hypothesis to be assessed is that the proportion of patients with maintained or increased level of 90-minute at 12 months as compared to baseline will be greater in subjects receiving combination therapy than for placebo subjects.

The analysis of the primary outcome will initially involve a two sample test of proportions comparing the proportion of patients in the combination therapy group maintaining or increasing 90-C-peptide with respect to baseline with the proportion of placebo subjects with 90-minute C-peptide that is maintained or increased from baseline value. A covariate-adjusted analysis will additionally be performed by way of a logistic regression model, with a categorical index of treatment group adjusted for baseline Treg proportion and age and time since diagnosis; this can provide us with adjustment for potential confounding of these factors and/or provide increased efficiency and precision by including these potentially significant explanatory variables.

10.4.3. **Supportive Analyses of the Primary Endpoint(s)/Outcome(s)**
90-min C-peptide measured at 4, 8 and 12 months in the different treatment groups will additionally be fit to a mixed linear regression model, allowing estimation and testing of means and differences between groups at each time point, while simultaneously accommodating the correlation arising from the longitudinal study design in estimates of variances used in tests of significance. We will also estimate and test the differential rate of change in mean 90-min C-peptide over time between these
groups, by incorporating an interaction term between time point and treatment group into the models. Although this investigation is not specifically powered to test this interaction, this might provide us with useful insight as to the differences in the effect of combination therapy over time on 90-min C-peptide.

10.4.4. Descriptive Analyses

In addition to the detailed statistical analysis described above, descriptive analysis will include reporting and comparison baseline characteristics of the study subjects to evaluate whether any substantial differences exist between the placebo and treated groups for key variables such as age, gender, BMI, HbA1c, baseline C-peptide, insulin requirements and other variables such as concomitant use of other medications of study completion, to determine any potential bias. These will involve standard two sample comparisons such as T-tests for continuous variables (possibly transformed when necessary to preserve distributional assumptions) and Chi-square or Fisher’s exact tests for categorical variables. As described earlier, potentially confounding factors arising from imbalance will be included into more formal statistical models of the investigation.

10.5. Interim Analyses

The DSMB will be convened to review safety and efficacy data. Descriptive interim analyses will include distributions of endpoints, and adverse events. Interim analyses will be conducted periodically during the study and will be reviewed by the DSMB for assessment of effectiveness and safety. Group-sequential spending function with an O’Brien-Fleming boundaries maybe used to protect the type I error probability from early and multiple testing and to assess the significance of the interim results that emerge during the trial.

10.5.1. Interim Analysis of Efficacy Data

Interim analysis for efficacy will be planned when half the subjects have reached their endpoint. However we note that this is a small trial and if we were to consider a priori planning for interim analysis the limited number of observations could lead to unstable estimates of efficacy. This can be further discussed with the DSMB. The inflation factor needed for augmenting sample size to preserve power if we were to plan for interim analysis at one look with group sequential methods using standard O'Brien-Fleming boundaries is 1.02, which does not significantly affect the parameters of our design (sample size needs to be inflated by 1.02).

10.5.2. Interim Analysis of Safety Data

Interim analysis may be conducted as recommended by the DSMB, to review safety data, including metabolic, immunological assessments and adverse events. The DSMB may recommend early stopping if there is sufficient evidence to conclude that the investigational treatment is harmful based on interim analysis of safety endpoints.

At any time, if there are significantly more adverse events in the experimental arm based on Fisher’s exact tests for comparison, early termination should be considered. For example, a scenario where 9 patients have enrolled with 6 in active treatment arm and 3 in the placebo arm with 5 adverse events
in the treatment arm and 0 in the placebo arm would be considered significantly increased likelihood of adverse events in the treatment arm and would potentially result in trial termination. The same holds in the scenario where 15 patients have been enrolled with 10 in treatment arm and 5 in the placebo arm, where the treated group realizes 9 adverse events while the placebo group realizes only 1. Similar scenarios exist throughout the trial and at any time if the exact test comparing groups under the null that the likelihood of adverse events is equal between groups exceeds a significance threshold of 0.05, this would warrant early termination.

10.5.3. Futility Analysis

Futility is unlikely to be shown during a one year treatment period, but the DSMB can decide to terminate the study should futility be shown. We do not intend to stop the study for futility as we intend to obtain an estimate and 95% confidence interval for the effect of treatment between groups at the 1 year mark using the full information offered by our design. Additionally, not stopping for futility incorporates the consideration that the C-peptide AUC curves of treated and placebo groups may separate later on follow-up, as AUC values decline further in the placebo group. Essentially all type 1 diabetes trials have been allowed to reach their one-year endpoint, even those that showed no efficacy.

10.6. Statistical Hypotheses

Primary hypothesis:

- **Null**: Patients receiving combination supplement therapy and patients in the Vitamin-D alone group have comparable proportions with maintained or increased C-peptide production, assessed by the measurement of the stimulated 90-minute C-peptide at one year of follow up.

- **Alternative**: Patients receiving combination therapy have higher proportions with maintained or increased C-peptide production, assessed by the measurement of the stimulated 90-minute C-peptide as compared to the proportion of patients with maintained or increased C-Peptide in the placebo group at one year of follow up.

10.7. Sample Size Considerations

**Metabolic primary outcome**

Sample size considerations correspond to the primary hypothesis which is that the proportion of patients with maintained or increased 90-min C-peptide at 12 months compared to baseline value is greater in the combination therapy group than in the placebo group. Standard power calculations for two sample tests of proportions indicate that 12 subjects in each group are needed to achieve 80% power to detect differences between less than 5% in the placebo group and at least 50% in the combination therapy group. Allowing for 10% dropout/attrition, sample size considerations include an allowance for 10% of the subjects to have missing data (one-year MMTT was not done or subject withdrew prior to the one-year assessment).
Primary endpoints should be available for all enrolled subjects. An exception will be if a death occurs or if the subject withdraws consent to be followed, although we expect this to be very limited. We also have included consideration for attrition in our design. Should there be any missing data, missing data will be assessed for mechanism of missingness and to see if missing at random assumptions are valid. If necessary, appropriate imputation strategies can be applied for sensitivity analysis. We will explore the data to assess if missingness at a given time point is related to observed data at the previous time point. If we find that, conditional on treatment group, observed values strongly predict subsequent values where observed, but are not related to missingness at subsequent time points, we may regard the missing data as a random sample of previously observed data.

11. ETHICAL CONSIDERATIONS & COMPLIANCE WITH GOOD CLINICAL PRACTICE

11.1. Statement of Compliance
The study will be conducted in accordance with the protocol, Good Clinical Practices, the relevant ICH guidelines, the applicable regulatory requirements, and the ethical principles that have their origins in the Declaration of Helsinki. As required by United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) (21 CFR 56) and the Declaration of Helsinki, the study protocol, amendments, and Informed Consent form will be reviewed and approved, according to 21 CFR §50 and §56, respectively, by University of Miami’s IRB. Any amendments to the protocol or consent materials must also be approved before they are implemented.

11.2. Informed Consent
The consent process will be conducted by qualified study personnel (the Study Coordinator and/or Investigator or other designee). All participants (or their legally acceptable representative) must read, sign and date a consent or assent form prior to participation in the study, and/or undergoing any study-specific procedures.

The informed consent form must be updated or revised whenever there is new clinically significant information applicable to the safety of the participants when indicated for a protocol amendment, and/or whenever any new information becomes available that may affect a patient’s participation in the study.

11.3. Study Subject Confidentiality
The investigational site participating in this study will maintain the highest degree of confidentiality permitted for the clinical and research information obtained from subjects. As a part of the quality assurance and legal responsibilities of an investigation, the investigational site must permit authorized representatives of the Quality Assurance division of University of Miami and regulatory agencies to examine (and when required by applicable law, to copy) records for the purposes of quality assurance reviews, audits and evaluation of the study safety and progress. Unless required by the laws permitting copying of records, only the coded identity associated with documents or other participant data may be copied (obscuring any personally identifying information). Authorized representatives, as noted above,
are bound to maintain the strict confidentiality of medical and research information that may be linked to identify individuals. The investigational site will normally be notified in advance of auditing visits. Study records with the study subject’s information for internal use at the clinical site will be secured at the study site during the study. At the end of the study, all records will continue to be kept in a secure location. There are no plans to destroy the records.

Study subject data, which is for reporting purposes, will be stored at the Diabetes Research Institute. Case report forms will identify participants by the unique Identification Number. At the end of the study, all study databases will be archived at the Center, and the data collection forms will be saved for long-term storage.

Stored samples including genetic samples could be utilized to learn more about causes of type 1 diabetes, its complications (such as eye, nerve, and kidney damage) and other conditions for which individuals with diabetes are at increased risk, and how to improve treatment. The results of these future analyses, and any mechanistic studies will not be made known to the participant.

12. STUDY ADMINISTRATION

This study is investigator initiated study sponsored by the investigators from Diabetes Research Institute. Funding will cover the costs of administration and laboratory tests associated with this study during the participant’s period of follow-up and procedures related to drug administration. Study drugs will be free of charge for the participant’s entire length of treatment.

12.1. Groups and Committees

12.1.1. Protocol Development Committee

As acknowledged on the preface of this study protocol, protocol development committee met periodically over four months to finalize this protocol. Members of this committee bring interdisciplinary and translational expertise in pediatrics, immunology, transplantation and endocrinology of T1D, research nurse, research pharmacist and regulatory experts. Committee consists of Subject Matter Experts with unique and proven expertise in different immune pathways involved in T1D.

12.1.2. Clinical Site

The study will be conducted at Diabetes Research Institute and Mailman Center for Child Development. Principal Investigators of the participating clinical site will oversee all operations. The clinical sites will conduct the trial and collect all laboratory and data collection form information for analysis. Clinical research team meets every Friday of the week to discuss development and issues related to all clinical research studies at the institute and facilitate evaluation of the trial management.

12.1.3. Medical Monitor for the Clinical Protocol

This trial includes the medical monitor independent of the study (George Burke, M.D., Professor of Surgery at the University of Miami Miller School of Medicine).
12.1.4. Clinical Site Monitoring
In order to conduct this study consistent with established research principles and ICH-GCP guidelines, there will be site visits conducted during the study to evaluate study conduct. CRORS is part of the Research, Research Education & Innovative Medicine (RIM) Department, within the Miller School of Medicine at the University of Miami. The CRORS is independent of the Diabetes Research Institute and will provide source data verification and periodic monitoring for patient enrollment, compliance with protocol procedures, completeness and accuracy of data entered on the case report forms (CRFs), and the occurrence and reporting of adverse events (AEs) and serious adverse events (SAEs). The site will be monitored by the Clinical Research Associates from the CRORS (Clinical Research Operation and Regulatory Support).

12.1.5. Data and Safety Monitoring Board (DSMB)
The members of the DSMB are independent and serve in an individual capacity to provide their expertise and recommendations. They will review the 90 day data of the first 24 subjects, and then periodically review as per the charter and evaluate the accumulated study data for participant safety, study conduct and progress, and, when appropriate, efficacy, and make recommendations to study investigators concerning the continuation, modification, or termination of the trial. The DSMB members are experts in the field of T1D immunotherapy and will consider study-specific data as well as relevant background knowledge about the disease, test agents, and patient population under study. All adverse events will be recorded on the adverse event forms, which will be provided to the local IRBs, per their reporting requirements. The DSMB will independently evaluate whether the adverse events constitute grounds to discontinue the study.

12.1.6. DRI Office of Regulatory Support
This office of Quality Assurance and Regulatory Affairs provides standardized auditing functions, educational training, and regulatory support for clinical research at the Diabetes Research Institute.

The HSRO provides administrative support for the University of Miami IRBs, which review proposed research involving human subjects to ensure the protection of those subjects and regulatory compliance.

12.1.8. Clinical Research Centers
Pediatric endocrinology clinics at the Mailman Center for Child Development and adult endocrinology clinics at Diabetes Research Institute and Clinical Translational Research Site at the University of Miami Miller School of Medicine provide comfortable, safe and effective environment to conduct professional, high-quality research involving human subjects.
12.1.9. Investigational Drug Services (Research Pharmacy)

The Investigational Drug Service (IDS) was established to provide pharmacy support to investigators in managing randomized, clinical trials at the University of Miami. The IDS also has the capability to dispensings complete investigational therapies and as drug safety experts therein can provide customized value that is increasingly recognized as a mechanism for assuring safety of study patients, ensuring adherence to protocol guidelines, and minimizing the liability associated in conducting drugs or supplement trials.

12.1.10. Core Laboratories

Core laboratories participating in the study include:

- Clinical research laboratories routinely providing services to the University of Miami.
- The Laboratory of Dr. Alberto Pugliese at the Diabetes Research Institute, University of Miami, Miami, Florida, where samples from patients will be processed, divided in aliquots, frozen as needed for future analysis.

12.2. Preservation of the Integrity of the Study

All presentations and publications using study data must protect the main objectives of the trial. Data integrity will be maintained and the investigators will publish study results and will apply accepted academic policies and regulations governing the publication.

12.3. Participant Reimbursement and Compensation

Participants will not be compensated for visits attended in the study. The supplement(s) during the course of the study will be provided at no charge to the subjects.

13. STUDY TIMELINE

It is anticipated that patient enrollment will occur during the first three years of the trial. All subjects will be followed until one year after initial treatment, with up to one year further follow-up after the treatment period has ended.
<table>
<thead>
<tr>
<th>Visit number</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5 F1</th>
<th>6 F2</th>
<th>7 F3</th>
<th>8 F4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days of the trial^1</td>
<td>𝜏</td>
<td>𝜏</td>
<td>120</td>
<td>240</td>
<td>360</td>
<td>480</td>
<td>600</td>
<td>720</td>
<td>840</td>
</tr>
<tr>
<td>Months</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>8</td>
<td>12</td>
<td>16</td>
<td>20</td>
<td>24</td>
<td>28</td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical Exam^2</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CBC with differential</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prothrombin time (PT/PT-INR)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Chemistries</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test^6</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample for genotyping</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Serum for antibodies</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanistic assessments^3</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Hemoglobin A1c</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Simulated C-peptide at 90 min</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMTT 4 hour</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Diabetes Assessments (insulin adjustment and Hypoglycemia awareness)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Clarke Score</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dispensing or Administration of Study Drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>• Omega-3 Fatty Acids + Vitamin-D OR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>• Vitamin-D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Vitamin D levels^4</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA/EPA Ratio</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Counting of Returned Study Drug</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subject 7-day blood sugar record and hypoglycemia log Review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medication Review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Experiences</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

1. Screening Visit: Screening MMTT must be at least 3 weeks after diagnosis and within one month (37 days) of randomization for recent onset T1D. For established T1D, screening must take place after 180 days of diagnosis.

2. Physical Exam: Routine exam at screening and quarterly, 3 Mechanistic Assessments: includes samples for RNA, plasma, serum, DNA, measures of B and T cell number and function. The schedule for these
assessments may vary as appropriate. At no time will the blood draw volume exceed what is allowable according to the subject’s body weight.

4. Vitamin D levels will be monitored every 4 months or more frequently at the discretion of the investigator in order to adjust dose to achieve target levels.

F1-F4 Follow-Up after 12 Months: Visits will be conducted approximately every 4 months (16, 20, and 24 months).

5. Pregnancy testing will be conducted in females in reproductive age at 4, 8, 12 and 16 months study visit.
REFERENCES

• Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL, Bergenstal RM, Harris B, Dubose SN, Miller KM, Beck RW (2013) Severe Hypoglycemia and Diabetic Ketoacidosis in Adults with Type 1 Diabetes: Results from the T1D Exchange Clinic Registry. J Clin Endocrinol Metab

Permission to Take Part in a Human Research Study

Title of Study: A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol Supplementation in Type 1 Diabetes (POSEIDON STUDY)

Principal Investigator: David Alejandro Baidal, M.D.,
Department: Diabetes Research Institute, University of Miami
Phone Number: 305 243-5321
Email Address: dbaidal@med.miami.edu , jsanchez@med.miami.edu
Study Contact Name: David Alejandro Baidal, M.D., Janine Sanchez, M.D.
Phone Number: 305 243-6913 24-hour contact number: 305-243-1000
Study Contact Email: dbaidal@med.miami.edu , jsanchez@med.miami.edu
Sponsor: Camillo Ricordi, M.D. and Rodolfo Alejandro, M.D.

READ THE FOLLOWING CAREFULLY

A person who takes part in a research study is called a research or study subject. In this consent form “you” always refers to the research subject. If you are the parent or guardian of a child who is participating, please remember that “you” means the child.

What you should know about this study:
• You are being asked to join a research study.
• The goal of medical treatment is to care for an injury or condition you have. The goal of research is to develop new knowledge for medical science. This is a consent form to participate in a research study.
• This consent form explains the research study and your participation in the study.
• Please read it carefully. Take as much time as you need.
• Please ask the study staff questions about anything you do not understand.
• After reading this form and talking with the research staff, you should know which parts of the study are experimental and which are standard medical care.
• You can ask questions now or any time during the study.
• Whether or not you decide to be part of the study, you can still get medical care as you normally would be able to. If you don’t want to be in the study, your doctor will continue to treat you.
• If you join the study, you can change your mind later.
• You can quit the study at any time.
• If you decide to quit the study, you will not lose any medical benefits.

PURPOSE
The purpose of this research study is to find out what effects (good and bad) OMEGA-3 and Vitamin D has on you and your condition. This study includes the use of the following drugs: OMEGA-3 and Vitamin D. The use of the study drug combination is considered experimental.

• 28 participants will be assigned to receive Omega-3 Fatty Acids and Vitamin D combination following randomization, and then will be followed for an additional year.
• 28 participants will receive only Vitamin D.

PROCEDURES
After screening to determine eligibility, study visits will be monitored closely and first dose of the medications (Omega-3 Fatty Acids plus Vitamin D OR Vitamin D alone) will be given at the site.

Randomization means that you are assigned to a group by chance (like flipping a coin). You will have an equal chance of being placed in any group. You will be assigned to 1 of the study groups described below.

You will be required to come to visits at baseline (day 0), and every four months thereafter (month 4, 8, and 12) and consist of treatment adherence and outcome assessments. You will be provided with supply of study drugs to take home and administer orally. You will be educated and trained for the drug administration and study personnel will evaluate drug returns and treatment adherence. You will be advised to bring the used medication back to site during your next visit. At the end of one year, you will continue with assessments up to an additional one year.

Biological specimens collected in this trial may be used to reevaluate biologic responses as new research tools become available. The specimens will be stored at the laboratory of the individual investigators at Diabetes Research Institute of University of Miami. Specimens for future mechanistic studies will be obtained throughout the study. Residual specimens may be used by the investigators for studies of immunologic mechanisms involved in T1D. If you choose to withdraw from the study early, you will have the option to have your samples destroyed.

The following schedule shows the tests that you will have done each time you return to the clinic. An “X” indicates the time-point when a particular test is completed.

<table>
<thead>
<tr>
<th>Study visits</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Months</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>8</td>
<td>12</td>
<td>16</td>
<td>20</td>
<td>24</td>
<td>28</td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical Exam²</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood Tests</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MMTT 4 hour</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Diabetes Assessments (insulin adjustment and Hypoglycemia awareness)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Dispensing or Administration of Study Drug</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>• Omega-3 Fatty Acids + Vitamin-D OR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Vitamin-D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Counting of Returned Study Drug</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Subject 7-day blood sugar record and hypoglycemia log.</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Concomitant Medication Review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse Events</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
General assessments include:

- Medical history: To determine if there are any clinically significant diseases or medical procedures other than the disease under study.
- Physical examination: Includes any body system with clinical signs or reported symptoms of adverse events and weight loss.
- Concomitant medications
- Adverse events

HOW LONG WILL I BE IN THIS STUDY?

You will be treated and followed for one year, and will be followed for up to one additional year beyond the period of treatment. Enrollment is expected to occur over three years.

RISKS AND DISCOMFORTS

There is always a risk to your privacy when you share information about yourself. However, the information that we collect from you in this study will be kept confidential, and there are practices in place to protect your personal information.

Pregnancy: Pregnant and lactating women will not be included in the study. Sexually active females must have a negative pregnancy test prior to enrolling in the study and will be required to use at least two FDA approved birth control during the study. If a subject who was previously sexually inactive becomes sexually active, she will be counseled about the need to use a reliable forms of birth control. Subjects will be requested to avoid pregnancy for 6 months following the last study administration and instructed to use birth control. If, following initiation of the study product(s), it is subsequently discovered that a study subject is pregnant, the study product(s) will be permanently discontinued in an appropriate manner (e.g. dose tapering if necessary for subject safety).

Allergic reaction: As with any drug, it is possible that you could experience an allergic reaction to OMEGA-3, or Vitamin D. Such allergic reactions include: itching, skin rash, sudden drop in blood pressure, loss of consciousness and/or associated with seizures, including the possibility of death.

Blood draw risks: Drawing blood may cause temporary pain from the needle stick, bruising or swelling at the site, and rarely, infection or fainting.

Hypoglycemia: This medication may affect your blood sugar too much (hypoglycemia). This could make you feel tired, dizzy, sweaty, and/or nauseated. Also, it could cause your heart to feel as if it is racing. There may also be other effects. Untreated hypoglycemia could cause convulsions, loss of consciousness, and can lead to death.

Omega-3 fatty acids may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: burping, heartburn, stomach pain or discomfort, joint pain, vomiting, constipation, diarrhea, nausea, change in the sense of taste. Omega-3 fatty acids may cause other side effects.

Please let your study doctor know if you are allergic to:

- Omega-3 fatty acids including omega-3-acid ethyl esters, icosapent ethyl esters, and omega-3-
carboxylic acids; fish, including shellfish (clams, scallops, shrimp, lobster, crayfish, crab, oyster, mussels, others); any other medications; or any of the ingredients in omega-3 fatty acid capsules. Ask your pharmacist for a list of the ingredients.

- What other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); antiplatelet medications such as cilostazol (Pletal), clopidogrel (Plavix), dipyridamole (Persantine, in Aggrenox), prasugrel (Effient), and ticlopidine; beta-blockers such as atenolol (Tenormin, in Tenoretic), labetalol (Trandate), metoprolol (Lopressor, Toprol XL, in Dutoprol), nadolol (Corgard, in Corzide), and propranolol (Inderal, Innopran XL, in Inderide); diuretics ('water pills'); estrogen-containing contraceptives (birth control pills, patches, rings, and injections); and estrogen replacement therapy. Your study doctor may need to change the doses of your medications or monitor you carefully for side effects.

- If you have atrial fibrillation or atrial flutter (conditions in which the heart beats irregularly); or liver, thyroid, or pancreatic disease.

- If you become pregnant while taking omega-3 fatty acids, call your doctor.
- Ask your doctor about the use of alcoholic beverages while you are taking omega-3 fatty acids.

Eat a low-fat, low-cholesterol diet. Be sure to follow all exercise and dietary recommendations made by your study doctor.

**Vitamin D** Too much vitamin D can make the intestines absorb too much calcium. This may cause high levels of calcium in the blood. High blood calcium can lead to:

- Calcium deposits in soft tissues such as the heart and lungs
- Confusion and disorientation
- Damage to the kidneys
- Kidney stones
- Nausea, vomiting, constipation, poor appetite, weakness, and weight loss

Please maintain a consistent diet during the course of the study. The body makes vitamin D when the skin is directly exposed to the sun. That is why it is often called the "sunshine" vitamin. Most people meet at least some of their vitamin D needs this way. Very few foods naturally contain vitamin D. As a result, many foods are fortified with vitamin D. Fortified means that vitamins have been added to the food. Fatty fish (such as tuna, salmon, and mackerel) are among the best sources of vitamin D. Beef liver, cheese, and egg yolks provide small amounts. Mushrooms provide some vitamin D. Some mushrooms you buy in the store have higher vitamin D content because they have been exposed to ultraviolet light. Most milk in the United States is fortified with 400 IU vitamin D per quart. Most of the time, foods made from milk, such as cheese and ice cream, are not fortified. Vitamin D is added to many breakfast cereals. It is also added to some brands of soy beverages, orange juice, yogurt, and margarine. Check the nutrition fact panel on the food label.

**Unknown Risks:** The experimental drug may have side effects that no one knows about yet. The researchers will let you know if they learn anything that might make you change your mind about participating in the study. Taking the study drug may involve unknown risks to a pregnant woman, an embryo, fetus (unborn baby) or nursing infant. Therefore, if you are pregnant, planning to become pregnant or are breastfeeding a child, you cannot participate in this study.

Keep all appointments with your study doctor and the laboratory. Your study doctor will order certain lab tests to check your body's response to omega-3 fatty acids and/or vitamin D.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit study doctor or your primary physician and hospital visits. It is also important information to carry with you in case of emergencies.

**BENEFITS**

We cannot promise that you will receive any benefit from being in the study. If you take part in the study, other people with Type 1 Diabetes may be helped in the future by what researchers learn from the study.

The benefits to you from being in this study may be include the recognized benefits of being in a clinical study, including close monitoring and additional resources available to maintain tight glycemic control offered to all subjects, regardless of group assignment. These additional resources include frequent in-person and other contact with study associate diabetes educator throughout the duration of the study. Further, the intervention has the prospect of direct benefit to a given subject and is likely to yield general knowledge about T1D which is of importance for the understanding and amelioration of T1D. The study procedures, while greater than minimal risk, offers the possibility of benefit due to the close monitoring for all participants.

Moreover, the proposed studies will produce new information about the blood glucose management and its regulation, in the context of T1D and in relation to therapy that would be relevant to other autoimmune diseases.

**ALTERNATIVES**

If you decide not to be in this study, there are other choices available. These include ongoing type 1 diabetes management with insulin, diet and exercise under the supervision of your endocrinologist. Ask the researcher to talk about these choices with you. You do not need to be in this study to receive treatment for your condition. This is not a treatment study. Your alternative is not to participate in this study.

**COSTS**

This study is investigator initiated study sponsored by the investigators from Diabetes Research Institute. Funding will cover the costs of administration and laboratory tests associated with this study during the participant’s period of follow-up and procedures related to drug administration. Study drugs will be free of charge for the participant’s entire length of treatment.

**PAYMENTS TO PARTICIPANTS**

Participants will not be compensated for visits attended in the study. The supplement(s) during the course of the study will be provided at no charge to the subjects.

**COMMERCIAL ISSUES**
Any blood, urine, tissue, or other biological specimens obtained for the purposes of this study become the exclusive property of the University of Miami. The University of Miami may retain, preserve, or dispose of these specimens and may use these specimens for research which may result in commercial applications. You will not receive money for donating blood, urine or tissue samples nor will you receive money from any future proceeds as a result of this research project.

COMPENSATION FOR STUDY-RELATED INJURY

Although risks are unlikely, if injury should occur, treatment will in most cases be available. If you have insurance, your insurance company may or may not pay for these costs. If you do not have insurance, or if your insurance company refuses to pay, you will be expected to pay. Funds to compensate for pain, expenses, lost wages and other damages caused by injury are not available

CONFLICT OF INTEREST

One of the study doctors has disclosed that he/she has a personal interest related to this study. You may ask any questions necessary to assure yourself that this relationship has not overly influenced the conduct of this research study. If you require further information, please contact the study doctor with questions or concerns.

VOLUNTARY PARTICIPATION / WITHDRAWAL FROM STUDY

Being in this study is up to you. You can say no now or leave the study at any time later. This will not affect your care or benefits at UM/Jackson Memorial Hospital. The researcher may remove you from the study if he/she believes that staying in the study is no longer in your best interest. If you stop being in the study, the study staff will stop collecting new information about you but they may need to use the information they have already collected.

We will tell you about any new information or changes in the study that might change your decision to stay in the study. You may be asked to sign a new consent form if this occurs.

The study doctor or the sponsor may remove you from the study without your approval.

CONFIDENTIALITY

The investigational site participating in this study will maintain the highest degree of confidentiality permitted for the clinical and research information obtained from subjects. As a part of the quality assurance and legal responsibilities of an investigation, the investigational site must permit authorized representatives of the Quality Assurance division of University of Miami and regulatory agencies to examine (and when required by applicable law, to copy) records for the purposes of quality assurance reviews, audits and evaluation of the study safety and progress. Unless required by the laws permitting copying of records, only the coded identity associated with documents or other participant data may be copied (obscuring any personally identifying information). Authorized representatives, as noted above, are bound to maintain the strict confidentiality of medical and research information that may be linked to identify individuals. The investigational site will normally be notified in advance of auditing visits. Study records with the study subject’s information for internal use at the clinical site will be secured at the study site during the study.
At the end of the study, all records will continue to be kept in a secure location. There are no plans to destroy the records.

Study subject data, which is for reporting purposes, will be stored at the Diabetes Research Institute. Case report forms will identify participants by the unique Identification Number. At the end of the study, all study databases will be archived at the Center, and the data collection forms will be saved for long-term storage. Your name will not appear in any publications about this study.

Your information may be looked at and/or copied for research or regulatory persons by:
- The Food and Drug Administration (FDA).
- Department of Health and Human Services (DHHS).
- other government agencies.
- other University of Miami employees for audit and/or monitoring purposes.
- your health care providers.

We are asking you to let us collect some information from your medical records for this study. We will not need to look at all your records. Instead, we will use a computer to find information about your use of health care services, including:
- clinic visits
- lab test results
- trips to the hospital
- medicines

A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

INCLUSION OF CERTAIN STUDY TEST AND PROCEDURE RESULTS IN YOUR UNIVERSITY OF MIAMI MEDICAL RECORD

If you are or have been a patient at a UM facility, then you will have a UM medical record. We use an electronic medical record system known as UChart, which improves access to information important to your medical care.

Since this study is related to your medical care, the UChart will show that you are in a research study and a copy of this signed consent form will be included. In order to provide as complete a record as possible, some of your study-related research information may also be placed in UChart. This information will be available to UM doctors, nurses and other authorized staff who may not be part of the research team but who are involved in providing you medical care. The confidentiality of the results and other documents in UChart will be governed by laws, such as HIPAA, that concern medical records.

We suggest that you tell any non-UM doctors that you are in a research study and that more information may be made available at your request.

The research team may use your information to notify you of appointments, send you appointment reminders, or schedule additional appointments.
WHOM TO CONTACT

If you have any questions about the study, or if you are hurt while in this study, you may contact David Alejandro Baidal, M.D. or Janine Sanchez, M.D. at 305-243-6913

If you have any questions about your rights as a research subject, please contact the University of Miami’s HUMAN SUBJECTS RESEARCH OFFICE (HSRO), at 305-243-3195.

PARTICIPANT’S STATEMENT/SIGNATURE

• I have read this form and the research study has been explained to me.
• I have been given the chance to ask questions, and my questions have been answered. If I have more questions, I have been told who to call.
• I agree to be in the research study described above.
• I will receive a copy of this consent form after I sign it.

_________________________________________  __________________________
Signature of Participant                                  Date

_________________________________________
Printed Name of Participant

Use the section below if this form is used for parental consent

_________________________________________
Printed Name of Child

_________________________________________  __________________________
Signature of Parent/Legally Acceptable Representative    Date

_________________________________________
Printed Name of Parent/Legally Acceptable Representative

_________________________________________
Printed Name of Child (if applicable)

_________________________________________  __________________________
Signature of Witness (if applicable)                      Date

_________________________________________
Printed Name of Witness

_________________________________________
Signature of Person Obtaining Consent                    Date

_________________________________________
Printed Name of Person Obtaining Consent
Assent is required for participant minors age 6 to 17 years. A separate assent form has been provided.
Assent (Permission) to Take Part in a Human Research Study  
For Child Participants 6-17 Years Old

Title of Study: A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol Supplementation in Type 1 Diabetes  
Principal Investigator: David Alejandro Baidal, M.D.  
Department: Diabetes Research Institute, University of Miami  
Phone Number: 305 243-5321 24-hour contact number: 305-243-1000  
Email Address: dbaidal@med.miami.edu, jsanchez@med.miami.edu  
Sponsor: Camillo Ricordi, M.D. and Rodolfo Alejandro, M.D.

READ THE FOLLOWING CAREFULLY

We want to tell you about a research study we are doing and ask if you want to be part of it. People do research to try to find answers to questions. If you do not understand something, just ask us. We want you to ask questions now and anytime you think of them.

We are working to find out more about the effects of OMEGA-3, and Vitamin D on your diabetes. Specifically, to determine if these supplements might help you control your blood glucose levels in combination with your current treatment, and medication.

You are being asked to participate in this study since you have been diagnosed with Type 1 Diabetes. About 28 children and 28 adults will be in the study.

Both you and your parent(s) must agree to you being in this study. You do not have to be in this study if you do not want to, even if your parent(s) said “yes”. If you or your parents do not want you to be in this study, here are some things that you may be able to do: Continue to manage your blood glucose with Insulin as standard of care therapy along with diet and exercise under the supervision of your endocrinologist.

The purpose of this research study is to test the safety and possible harms of Vitamin D and OMEGA-3 when it is given to people at different dose levels. The researchers want to find out what effects (good and bad) OMEGA-3 and Vitamin D has on you and your condition.

If you decide to be in this study, this is what will happen:

- Randomization means that you are assigned to a group by chance (like flipping a coin). You will have an equal chance of being placed in any group. You will be assigned to 1 of the study groups described below.
  - 14 children will be assigned to receive Omega-3 Fatty Acids and Vitamin D combination following randomization, and then will be followed for an additional year.
  - 14 children will receive only Vitamin D.
- After screening to determine eligibility, study visits will be monitored closely and first dose of the medications (Omega-3 Fatty Acids plus Vitamin D OR Vitamin D alone) will be given at site. You will have visits at baseline (day 0), and every four months thereafter (month 4, 8, and 12) that will include to assess the effect of treatment. You will be provided with supply of study drugs to take home and administer orally based on
randomization. You will be educated and trained for the drug administration and study personnel will evaluate drug returns and treatment adherence. You will be advised to bring the used medication back to site during your next visit. At the end of one year, all subjects will continue with assessments up to an additional one year (months 16, 20 and 24).

There is little chance that you will be helped by being in this study. We might also find out things that will help other children someday.

There is a chance that you could have problems that make you feel bad because of this study. Some problems that might happen are:

- **Omega-3 Fatty Acids** may cause gastrointestinal side-effects including stomach pain or discomfort, burping, heartburn, vomiting, constipation, diarrhea, nausea, and change in the sense of taste. Joint pain may be a side effect as well.

- **Vitamin D** in very high doses can make the intestines absorb too much calcium which can cause high levels of calcium in the blood (hypercalcemia). This can cause side effects including nausea, vomiting, constipation, poor appetite, weakness, weight loss, confusion and disorientation. Hypercalcemia can also lead to kidney stones, damage to the kidneys, and cause calcium deposits in heart and lungs. We will monitor your blood levels to minimize these risks.

- **Allergic reaction**: As with any drug, it is possible that you could experience an allergic reaction to OMEGA-3, or Vitamin D. Such allergic reactions include: itching, skin rash, sudden drop in blood pressure, loss of consciousness and/or associated with seizures, including the possibility of death.

- **Blood draw risks**: Drawing blood may cause temporary pain from the needle stick, bruising or swelling at the site, and rarely, infection or fainting.

- **Hypoglycemia**: This medication could lower your blood sugar too much (hypoglycemia). This could make you feel tired, dizzy, sweaty, and/or nauseated. Also, it could cause your heart to feel as if it is racing. There may also be other effects. Untreated hypoglycemia could cause convulsions, loss of consciousness, and can lead to death.

**Omega-3 fatty acids** may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: burping, heartburn, stomach pain or discomfort, joint pain, vomiting, constipation, diarrhea, nausea, change in the sense of taste. Omega-3 fatty acids may cause other side effects.

Please let your study doctor know if you are allergic to
- Omega-3 fatty acids including omega-3-acid ethyl esters, icosapent ethyl esters, and omega-3-carboxylic acids; fish, including shellfish (clams, scallops, shrimp, lobster, crayfish, crab, oyster, mussels, others); any other medications; or any of the ingredients in omega-3 fatty acid capsules. Ask your pharmacist for a list of the ingredients.
- What other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following:
anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); antiplatelet medications such as cilostazol (Pletal), clopidrogel (Plavix), dipyridamole (Persantine, in Aggrenox), prasugrel (Effient), and ticlopidine; beta-blockers such as atenolol (Tenormin, in Tenoretic), labetalol (Trandate), metoprolol (Lopressor, Toprol XL, in Dutoprol), nadolol (Corgard, in Corzide), and propranolol (Inderal, Innopran XL, in Inderide); diuretics ('water pills'); estrogen-containing contraceptives (birth control pills, patches, rings, and injections); and estrogen replacement therapy. Your study doctor may need to change the doses of your medications or monitor you carefully for side effects.

- If you atrial fibrillation or atrial flutter (conditions in which the heart beats irregularly); or liver, thyroid, or pancreatic disease.
- If you become pregnant while taking omega-3 fatty acids, call your doctor.
- Ask your doctor about the use of alcoholic beverages while you are taking omega-3- fatty acids.

Eat a low-fat, low-cholesterol diet. Be sure to follow all exercise and dietary recommendations made by your study doctor.

**Vitamin D** Too much vitamin D can make the intestines absorb too much calcium. This may cause high levels of calcium in the blood. High blood calcium can lead to:

- Calcium deposits in soft tissues such as the heart and lungs
- Confusion and disorientation
- Damage to the kidneys
- Kidney stones
- Nausea, vomiting, constipation, poor appetite, weakness, and weight loss

Please maintain a consistent diet during the course of the study. The body makes vitamin D when the skin is directly exposed to the sun. That is why it is often called the "sunshine" vitamin. Most people meet at least some of their vitamin D needs this way. Very few foods naturally contain vitamin D. As a result, many foods are fortified with vitamin D. Fortified means that vitamins have been added to the food. Fatty fish (such as tuna, salmon, and mackerel) are among the best sources of vitamin D. Beef liver, cheese, and egg yolks provide small amounts. Mushrooms provide some vitamin D. Some mushrooms you buy in the store have higher vitamin D content because they have been exposed to ultraviolet light. Most milk in the United States is fortified with 400 IU vitamin D per quart. Most of the time, foods made from milk, such as cheese and ice cream, are not fortified. Vitamin D is added to many breakfast cereals. It is also added to some brands of soy beverages, orange juice, yogurt, and margarine. Check the nutrition fact panel on the food label.

**Unknown Risks:** The experimental drug may have side effects that no one knows about yet. The researchers will let you know if they learn anything that might make you change your mind about participating in the study.

Keep all appointments with your study doctor and the laboratory. Your study doctor will order certain lab tests to check your body's response to omega-3 fatty acids and/or vitamin D.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit study doctor or your primary physician and hospital visits. It is also important information to carry with you in case of emergencies.
**Females of child bearing potential** must have a negative pregnancy test prior to enrolling in the study and will be required to use at least two FDA approved birth control during the study. At every study visit the sexual activity of female participants of reproductive age will be reassessed. If a subject who was previously sexually inactive becomes sexually active, she will be counseled about the need to use a reliable forms of birth control. Female subjects in reproductive age will also be required to undergo pregnancy tests at each study visit up to 16 months. Subjects will be requested to avoid pregnancy for 6 months following the last study drug administration and instructed to use birth control. If, following initiation of the study drug, it is subsequently discovered that a study subject is pregnant, the study drug, will be permanently discontinued in an appropriate manner (e.g. dose tapering if necessary for subject safety).

It is important that you let the study doctors and your parents know if there is a problem right away.

The study is private. The study doctors will share what they learn about you with your parents (or guardian). The scientists and staff at the University of Miami working on the study and the part of the government that makes the rules about research will need to see what is learned, but they are not allowed to tell anyone about you. However, there is always a risk to your privacy when you share information about yourself. However, the information that we collect from you in this study will be kept confidential, and there are practices in place to protect your personal information.

You do not have to be in this study if you do not want to. It is up to you. If you say okay now, but you want to stop later, that is okay too. No one will be mad at you if you say no or change your mind. You can stop any time you want. All you have to do is tell the study doctor.

I have read this form or someone has read it to me. I can always ask the study doctor or their assistant a question about the study if do not understand something. I will be given a copy of this form.

Please check one box:
- ☐ **YES**, I want to be in this research study and I know that I can change my mind later.
- ☐ **NO**, I do not want to be in this study.

---

**Signature of Child** ____________________ **Date** ____________________

**Printed Name of Child**

*The following should be completed by the study member conducting the assent process if the child agrees to be in the study. Check all that apply:*
☐ The child is capable of reading and understanding the assent form and has signed above as documentation of assent to take part in this study.

☐ The child is not capable of reading the assent form, but the information was verbally explained to him/her. The child signed above as documentation of assent to take part in this study.

☐ The child had ample opportunity to have his or her questions answered.

__________________________________________________________  __________________
Signature of Person Obtaining Assent                              Date

____________________________________________________________________________
Printed Name of Person Obtaining Assent